The nature and strength of the association between regular ecstasy use and impaired executive function remains inconclusive, with some reports finding impaired executive function in ecstasy users [18, 294, 295], and others finding no association [296], or finding executive function impairments only in male ecstasy users [297]. A meta-analysis comparing executive function in ecstasy users and non-ecstasy using controls found a significant effect of ecstasy use on one component of executive function (updating), no effect on another (shifting) and mixed results when looking at other components (response inhibition and access to long-term memory) [298]. Polydrug use likely contributes to findings of impaired executive function seen in ecstasy users [280, 299]. Current research has not settled the question.

Investigations of the interaction between genotype and regular ecstasy use have supported differential effects upon reward-based attention or visual or verbal memory [300-302]. Given the small samples and uneven numbers with different genotypes, any conclusions await further support.

The relationship between ecstasy use and impulsivity has also been extensively examined, with some researchers reporting greater impulsivity in ecstasy users and others failing to find any differences, as seen in [45, 303]. Recent studies using both behavioral and self-report measures of impulsivity reached contradictory conclusions [304-306]. Two recent studies using the same measure of behavioral impulsivity in samples of heavy ecstasy users yet obtained different findings [304, 306]. It is possible that people who self-administer ecstasy may already possess above-average levels of sensation-seeking and impulsiveness. To date, all such studies have used retrospective study designs and cannot rule out this possibility, and studies published in the last two years suggest that polydrug use may be equally or more strongly related to impulsivity in ecstasy users [265, 307, 308]. The relationship between drug use, including ecstasy use, and impulsivity, is complex.

Not all studies report that ecstasy users fare worse on measures of cognitive function than controls. A number of recent reports detected little or no significant differences between ecstasy users and polydrug user controls in performance on tasks of cognitive function [293, 306, 309-313]though other studies continue to find consistent differences, particularly in verbal memory [252, 314-317]. Regular use of many substances, including alcohol, may affect cognitive function, with ecstasy being only one of those substances [318]. Several reports have found relationships between cognitive function and use of other drugs as well as or instead of ecstasy[301, 309, 311, 314, 319, 320].

7.5.5. Brain Activity In Humans

Brain imaging recorded during a task requiring keeping a target cue in mind, attention, and response inhibition also found changes in parietal activity when comparing performance under placebo or 75 mg MDMA [321]. MDMA increased activity in frontal areas and decreased activity in occipital sites as measured via fMRI [322], Subjects given MDMA exhibited similar brain activity when reading or encoding a word list, suggesting that they were investing similar effort into both tasks. Ten ecstasy user participants receiving a minimum dose of two doses of 1-1.25 mg/kg or 2.25-2.5 mg/kg MDMA exhibited signal decreases in bilateral visual cortex, caudate, superior parietal, and dorsolateral frontal regions 10 to 21 days later, with increased rCBF measured in two participants at a later time point [323]. However, a comparison between

heavy ecstasy users and non-user controls failed to find differences in baseline rCBF [269], and a report assessing changes before and after initial use found increased rCBF in only one area of the prefrontal cortex [324], suggesting that the changes seen by Chang and colleagues are a transient effect. Electroencephalography (EEG) recorded two hours after MDMA administration showed the following changes in EEG activity: overall increase in beta activity, reduction in alpha activity, and specific decreases in alpha and delta in frontal areas and increased frontotemporal beta signal [325]. The authors reported these EEG patterns as being similar to those seen with serotonergic and noradrenergic drugs, as well as, to a lesser extent, with dopaminergic drugs.

7.5.5.1. Changes in brain activity in ecstasy users

Studies comparing brain activity in ecstasy users and non-ecstasy using controls reported some but not many differences in brain activity. These included greater brain activation in the occipital cortex, with concomitant methamphetamine use contributing to increased activation to a visual stimulus [326]. The same group of researchers detected less within-region coherence in the thalamus in ecstasy users who averaged 29 episodes of use when compared with non-ecstasy-using controls [327]. A prospective study comparing brain activity before and after use of ecstasy failed to detect differences in working memory, attention or brain activity [293], suggesting a relationship between repeated, regular use of ecstasy and other drugs and changes in brain activation.

Researchers using slightly different methods have reported differing results. These include finding no differences between ecstasy user and polydrug user control in SERT sites [328], modest reductions in estimated SERT sites in ecstasy users versus non-drug using or cannabis-using controls [329], and an association between decreased SERT sites and lifetime ecstasy use [330]. This study also reported finding slightly fewer 5HT2A sites in both "ecstasy preferring" and "hallucinogen preferring" groups. Studies in very moderate ecstasy did not report an increase in this marker [324], and only one of three studies heavy users detected a change in 5HT2A receptor density. [331-333]. A prospective study in moderate ecstasy users also failed to find any chemical markers of neuronal injury, and only found decreased cerebral blood volume in the dorsolateral frontal cortex [324, 334]. A re-examination of brain imaging using the less specific SERT marker Beta-CIT indicate an inverse relationship between age of first use of ecstasy and mid-number of midbrain serotonin sites without detecting any relationship between age of first use and frontal SERT sites [335].

7.6. Long Term Effects in Ecstasy Users

Spurred on by nonhuman animal studies that found that repeated or high doses of MDMA damaged the axons of serotonin neurons, researchers began studying the effects of repeated non-medical or recreational use of ecstasy in humans [44-46, 336], and as described in the sections above. Early investigations possessed a number of methodological flaws, including retrospective design and poor matching of ecstasy users with appropriate controls [51, 83, 337]. Later studies sought to remedy some of these problems by using carefully matched polydrug user or cannabis user controls, or by relying on a sample with relatively low exposure to psychoactives, including alcohol [294, 296, 338, 339]. Some of these investigators also conducted longitudinal studies, comparing ecstasy users, sometimes alongside controls, at two separate time points [340-342]. Most studies suggested that heavy but not moderate ecstasy users had impaired verbal memory

and lower numbers of estimated SERT sites, with heavy use often defined as being at or greater than 50 times or tablets. Taken together, there is some risk of long-term effects with respect to number of estimated SERT sites in specific brain areas and performance on measures of memory. However, findings of changes in serotonin receptors or cognitive function after repeated ecstasy use are complicated by the possible impact of polydrug use and other potential pre-existing factors in retrospective reports, and the findings are not readily transferrable to use of MDMA in a therapeutic or research context.

7.7. Adverse Events Outside of Sponsor-Supported Studies

MDMA was administered to thousands of people prior to scheduling and many continue to use ecstasy around the world in various non-medical settings [14-18]. While a number of serious adverse events, including fatalities, have been reported after ecstasy use in unsupervised and uncontrolled settings, these events are relatively rare given the prevalence of ecstasy use [19, 20]. These include hyperthermia, including hyperthermia arising from "serotonin syndrome," psychiatric problems, hepatotoxicity, including acute liver failure arising from hypethermia and liver disease and hyponatremia [19, 40, 213, 216, 343]. Unexpected drug-related serious adverse events have not occurred in any of the human MDMA research studies so far. Set and setting may play a role in the development of some ecstasy-related adverse events, such as rigorous exercise, lack of attention to somatic cues, and too little or too much hydration resulting in hyperthermia or hyponatremia [212]. Hall and Henry address medical emergencies related to ecstasy use [344]. While case reports do not provide an appropriate basis for estimating the relative frequency of these events, they can provide information on the possibility of an event occurring. Most ecstasy-related emergency department admissions are the result of people experiencing anxiety or panic reactions after use and involve supportive care only [216, 274, 345]. A very extensive and systematic review reached similar conclusions concerning the frequency and nature of emergency department admissions, though also noting that owing to complexities of nonmedical and recreational use, the researchers found it hard to establish a lethal dose [40]. As is the case with fatalities, medical emergencies after ecstasy use are more likely to occur in men [216].

Other infrequently reported serious adverse events reported in ecstasy users and reported in case reports or series, include cardiac problems (as arrhythmias) [230, 231, 346], cerebrovascular events (such as cerebral hemorrhage or infarction [222, 223, 347], dermatological (dermatitis, guttate rash [348]), dental (tooth erosion, likely from frequent bruxism) [349-351], hematological, including aplastic anemia [352, 353], respiratory (pneumomediastinum and subcutaneous emphysema) [354-357], ophthalmic (sixth nerve palsy, chorioretinopathy (a condition associated with sympathomimetic use), corneal epitheliopathy (resulting from corneal exposure produced by consuming CNS depressants) [358, 359] , urological (as urinary retention) events[360-362].

A large number of the case reports published between 2008 and 2012 described conditions and emergencies that have previously appeared in the literature. They included 12 cardiac events [363-368], three hepatic events (including a cardiac and hepatic event) [369-371], five cerebrovascular events[347, 372, 373], four psychiatric events [374-376], three instances of hyponatremia [377-379], three cases of rhabdomyolysis and/or hyperthermia [380-382], three neurological cases [383-385], and single reports of facial rash (eruption) [386], urinary retention

[360], rhabdomyolysis of masseter muscle [387], aplastic anemia [388] and fatal allergic reaction [389]. The cases reported 13 deaths[365, 367-369, 377, 379, 382, 388, 389] (7 after cardiac events, two after hyponatremia, one after liver disease, one after hyperthermia and rhabdomyolisis, one after aplastic anemia and one after apparent allergic reaction. The death after aplastic anemia occurred from complications of treatment 17 months after the first admission from complications arising from immunosuppressant therapy given after bone marrow transplant. Detectable levels of MDMA in blood or urine are reported in seven of the 31 case reports, and range from 50 ng/mL (reported as less than 0.05 mg/L) in the allergic reaction [389]to 1500 ng/mL (reported as 1.5 mg/L) in a fatal case of hyperthermia and rhabdomyolisis [382].Only one of three neurological events provided information on MDMA levels, 0.83 ng/mL detected in the hair of a girl who developed encephalopathy [384], with a course and symptoms that are similar to those seen after central nervous system herpes infection. It is more difficult to associate event with MDMA when the compound is not detected or when detection is for amphetamines in general. Some events, such as valvular heart disease, acute hepatitis with gallbladder inflammation, or urinary retention self-reported daily use for months to years prior to the event, The case of valvular heart disease occurred in an individual who indicated that he had taken ecstasy daily for approximately 16 years, from age 17 to 33 years old.

The report of possible anaphylactic shock occurred in a 13-year old girl who had at least one previous exposure to ecstasy. Her friends reported that she experienced swelling lips after the first exposure. After approximately 1.5 tablets, the girl experienced nausea and vomited, and later had difficulty breathing. On admission she was hypothermic and hypotensive. None of the other individuals consuming tablets from the same batch underwent similar experiences. Autopsy found a massive brain edema as well as laryngeal edema and lung congestion. Chemical analyses ruled out hyponatremia. The reaction may have been to MDMA or to an adulterant in the tablet.

None of these events have occurred within the context of Phase 1 or Phase 2 human studies with MDMA.

7.8. Related Expected Adverse Events From Studies in Healthy Volunteers

Common expected adverse events of MDMA reported in Phase 1 studies in healthy volunteers include elevation in blood pressure and heart rate, increased anxiety or dysphoria, and dilated pupils [3-6]. Some reports indicated decreased rather than increased alertness [3]. Other common adverse events reported in controlled studies of MDMA include reduced appetite, dizziness, tight jaw or bruxism (tooth-grinding), difficulty concentrating, impaired gait or balance, dry mouth, and thirst. Participants in some studies also reported or exhibited changes in cognition, such as increases in speed of thought or thought blocking, facilitated imagination or facilitated recall [8], and unusual thoughts or ideas [5]. Other less commonly reported events include parasthesias (unusual body sensations) such as tingling or feeling hot or cold. MDMA produces anxiety in healthy volunteers [5, 6, 8]. These effects are transient and recede with the waning of drug effects. One study found that women were more likely than men to experience the most commonly reported adverse effects of MDMA, though men were more likely than women to experience the specific adverse events of nausea and sweating [6]. Adverse effects in women undergoing a single session of MDMA-assisted psychotherapy for PTSD were mild and appear to be similar to those in healthy controls [24].

Table 1: Acute Adverse events of MDMA Compiled from Literature of Human Trials with MDMA.

Data Source	**Prevalence Across Literature**		Downing 1986	Greer & Tolbert 1986	Vollenweider et al. 1998	Gamma et al. 2000	Liechti, Saur, et al. 2000	Liechti & Vollenweider 2000a	Liechti & Vollenweider 2000b	Harris et. al. 2002	Bouso et. al. 2008	Hysek 2011	Hysek et. al. 2012a	Hysek et. al. 2012b
	Placebo	**MDMA**												
N:	10-57	6-174	**10**	**29**	**13**	**16**	**14**	**14**	**16**	**8**	**4**	**16**	**16**	**16**
MDMA Dose(s):	0	0.5-4.18 mg/kg	1.76-4.18 mg/kg	75-150, 200 mg	1.7 mg/kg	1.7 mg/kg	1.5 mg/kg	1.5 mg/kg	1.5 mg/kg	0.5, 1.5 mg/kg	50, 75 mg	125 mg	125 mg	125 mg
Time post-drug	-	-	2-5 hr	N/A	0-3 hr	N/A	N/A	N/A	N/A	0-24 hr	24 hr	0, 3, 24 hr	3, 24 hr	3, 24 hr
Lack of Appetite	2%	68%	100%	97%	62%	63%	50%	50%	50%	63%	N/A	75%	56%	69%
Dry Mouth	N/A	64%	N/A	N/A	N/A	N/A	57%	57%	N/A	88%	N/A	N/A	63%	N/A
Jaw Clenching	0%	60%	60%	76%	62%	64%	57%	71%	44%	N/A	N/A	N/A	44%	50%
Concentration Issues	16%	53%	30%	3%	62%	50%	71%	50%	63%	88%	25%	75%	N/A	N/A
Thirst	4%	48%	N/A	N/A	38%	50%	57%	57%	38%	N/A	N/A	N/A	N/A	63%
Restlessness	0%	46%	N/A	N/A	31%	N/A	50%	29%	44%	N/A	N/A	50%	44%	69%
Restless Legs	0%	45%	N/A	N/A	46%	N/A	N/A	N/A	44%	N/A	N/A	N/A	N/A	N/A
Impaired Balance/Gait	0%	44%	70%	10%	62%	N/A	71%	43%	50%	N/A	N/A	N/A	N/A	N/A
Dizziness	2%	43%	N/A	N/A	31%	N/A	57%	21%	50%	75%	N/A	38%	N/A	N/A
Feeling Cold	4%	43%	N/A	N/A	23%	N/A	43%	N/A	N/A	75%	N/A	N/A	N/A	N/A

Perspiration	0%	40%	N/A	N/A	0%	50%	36%	N/A	N/A	50%	N/A	N/A	50%	50%
Sensitivity to Cold	7%	38%	N/A	N/A	38%	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Private Worries	23%	38%	N/A	N/A	38%	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Heavy Legs	0%	38%	N/A	N/A	38%	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Palpitations	0%	37%	N/A	N/A	31%	38%	43%	21%	N/A	63%	N/A	N/A	N/A	N/A
Drowsiness	50%	26%	N/A	14%	N/A	N/A	43%	N/A	N/A	N/A	50%	N/A	N/A	N/A
Data Source	**Prevalence** Across Literature		Downing 1986	Greer & Tolbert 1986	Vollenweider et al. 1998	Gamma et al. 2000	Liechti, Saur, et al. 2000	Liechti & Vollenweider 2000a	Liechti & Vollenweider 2000b	Harris et. al. 2002	Bouso et. al. 2008	Hysek 2011	Hysek et. al. 2012a	Hysek et. al. 2012b
	Placebo	**MDMA**												
N:	10-57	6-174	**10**	**29**	**13**	**16**	**14**	**14**	**16**	**8**	**4**	**16**	**16**	**16**
MDMA Dose(s):	0	0.5-4.18 mg/kg	1.76-4.18 mg/kg	75-150, 200 mg	1.7 mg/kg	1.7 mg/kg	1.5 mg/kg	1.5 mg/kg	1.5 mg/kg	0.5, 1.5 mg/kg	50, 75 mg	125 mg	125 mg	125 mg
Nystagmus	N/A	23%	80%	3%	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Hot Flashes	0%	23%	N/A	N/A	23%	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Nausea	4%	21%	10%	24%	8%	N/A	36%	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Trismus	N/A	21%	N/A	3%	N/A	N/A	57%	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Anxiety	0%	19%	N/A	17%	N/A	N/A	14%	N/A	N/A	N/A	50%	N/A	N/A	N/A
Inner Tension	0%	18%	N/A	3%	23%	N/A	43%	14%	19%	N/A	50%	N/A	N/A	N/A

Insomnia	0%	17%	0%	N/A	31%	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Weakness	0%	16%	N/A	3%	23%	N/A	36%	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Urge to Urinate	8%	15%	N/A	N/A	15%	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Tremor	0%	22%	N/A	3%	31%	N/A	21%	14%	N/A	N/A	N/A	56%	N/A	N/A
Muscle Ache/ Tension	N/A	20%	N/A	21%	0%	N/A	N/A	N/A	N/A	50%	N/A	N/A	N/A	N/A
Forgetfulness	0%	15%	N/A	3%	38%	N/A	N/A	N/A	N/A	N/A	25%	N/A	N/A	N/A
Fatigue	26%	15%	N/A	7%	8%	N/A	N/A	29%	N/A	N/A	50%	N/A	N/A	N/A
Parasthesias	0%	22%	N/A	3%	31%	N/A	N/A	N/A	N/A	75%	N/A	N/A	N/A	N/A
Lack of Energy	14%	14%	N/A	3%	N/A	N/A	29%	N/A	N/A	N/A	50%	N/A	N/A	N/A
Brooding	0%	12%	N/A	3%	N/A	N/A	29%	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Fainting	N/A	3%	N/A	3%	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Blurred Vision	N/A	3%	N/A	3%	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Lip Swelling	N/A	2%	N/A	3%	0%	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Headaches	N/A	11%	0%	3%	N/A	N/A	N/A	0%	N/A	50%	50%	N/A	N/A	N/A

8. Safety and Efficacy in Humans

In recent years, clinical investigation of the safety and efficacy of MDMA-assisted psychotherapy has become more feasible [390, 391]. The first double blind, placebo controlled, ascending dose U.S. Phase 1 study sanctioned by the FDA and supported by the Sponsor was conducted in 1994 [13, 202, 323]. In this study, MDMA was found to be generally tolerable in a clinical setting. These results lead to the first Phase 2 safety and efficacy study of low doses of MDMA-assisted psychotherapy in Spain on a small sample of women with chronic PTSD [24]. The study was originally approved for 29 subjects, but media and political pressure caused discontinuation of the study after only 6 subjects had been treated. The small sample size precluded statistical analysis for efficacy, yet the safety profile in the PTSD subject sample appeared promising as neither 50 nor 75 mg MDMA were found to increase psychopathological symptoms in this patient population. In July 2010, the Sponsor completed the first U.S. Phase 2 pilot study investigating the safety and efficacy of MDMA-assisted psychotherapy for patients with chronic treatment-resistant PTSD, protocol MP-1 [266]. Analysis of the results from this small pilot study from 21 subjects randomized to 125mg MDMA (N=13) or inactive placebo (N=8) suggest that MDMA-assisted psychotherapy can significantly decrease PTSD symptoms compared to placebo-assisted psychotherapy and appears to be safe when administered in a controlled therapeutic setting [266]. Findings from the long-term follow-up of MP-1 subjects suggest that therapeutic benefits were sustained over an average of 41 months post-treatment [22]. The Sponsor completed a second study in Switzerland, MP-2, with a randomized, active placebo controlled, double blind design. In this study, 12 subjects were randomized to receive 25mg or 125mg MDMA during three psychotherapy sessions (Oehen 2012). Results suggests clinically significant improvements in PTSD symptoms with a trend toward statistical significance [23]. Long-term follow-up data 12 months later suggest that therapeutic benefits continued to increase in this subject population. Additional phase studies are currently underway.

8.1. Safety of MDMA-assisted psychotherapy for PTSD

MP-1 enrolled 22 adult participants with PTSD with symptoms that failed to respond to at least one course of psychotherapy and at least one course of pharmacotherapy. An additional participant, a male veteran who refused prior treatment, was also enrolled after approval of an amendment by the FDA. The study enrolled eight women and five men, all were European-American, average age 40.6 years. Subjects enrolled had no history of major medical conditions, psychotic disorders, dissociative identity disorder, or personality disorders. Safety data obtained from this study included: scores from tests of cognitive function performed before and after study participation, vital signs and a measure of psychological distress during experimental sessions, expected adverse events for three experimental sessions, and adverse events that occurred during the study.

Two subjects (1 woman, 1 man) withdrew from the study after a single experimental session. The male subject withdrew from the study due to financial constraints on travel reimbursements, and the female subject withdrew from the study after experiencing a relapse of depression that required medication occurring 42 days after MDMA administration. Prior to relapse, the same subject had been hospitalized for benzodiazepine withdrawal while tapering medication. This subject reported reduction in PTSD symptoms even though the depression required medication.

There were no deaths during this study and no drug-related serious adverse events. Two unrelated, non-life threatening, serious adverse events occurred during the study. The first was a fractured clavicle from a vehicular accident in which the subject was a passenger, resulting in temporary disability and resolving with complete recovery. The second was an episode of vasovagal syncope, occurring 41 days after the second administration of MDMA and resolving with recovery to baseline. This subject had a medical history of fainting spells, and follow-up reports filed 15 months after the event indicate that it was not recurrent.

MP-2 enrolled fourteen adult participants (11 women, three men, average age 41.8 years) with PTSD with symptoms that failed to respond to at least one course of psychotherapy or pharmacotherapy. Most were of European ethnicity, but one woman was African and one man was Middle Eastern. Subjects enrolled had no psychotic disorders, dissociative identity disorder, or personality disorders. One subject had a previous history of breast cancer, but had been in remission for over 10 years and was not symptomatic at screening. Safety data obtained from this study included: vital signs and a measure of psychological distress during experimental sessions, expected adverse events for three to five experimental sessions, and adverse events that occurred during the study.

There were no serious drug-related adverse events in the MP-2 study. There was one death during the post-treatment follow-up period of the study from the metastasis of a brain tumor. The subject's death was the result of a previous condition and was determined to be unrelated to the study drug. There was one non-fatal, drug-unrelated serious adverse event that occurred during the study. A subject allegedly was hospitalized two weeks prior to administration of the study drug after exhibiting suicidal behavior following a conflict with her ex-husband. The subject was discharged from the hospital the next day, and did not exhibit suicidal or violent tendencies or any mental state requiring hospitalization prior to or after this event.

Two subjects (1 man, 1 woman) withdrew from the study as a result of adverse events occurring during the first experimental session. The first participant, who had received 125 mg MDMA experienced severe exacerbation of anxiety during the first experimental session. This event interrupted the experimental session and was treated with additional support during therapy until the drug effects dissipated. The anxiety was a part of PTSD symptoms present at baseline and its exacerbation was deemed to be probably related to drug administration. The second participant, who received 25 + 12.5 mg MDMA, experienced severe anxiety in reaction to being confronted with traumatic memories during the first experimental session, with the anxiety deemed possibly related to drug administration. The anxiety was treated with additional support in the form of therapy after the drug effects dissipated.

8.1.1. Vital signs

As expected, vital signs during experimental sessions indicate that MDMA elevates blood pressure and heart rate, but elevations return to baseline or near-baseline seven to eight hours after drug administration. Repeated measures analyses of variance using MP-1 average pre-drug, peak and final post-drug measurements of SBP, DBP, heart rate and body temperature after placebo versus MDMA detected significant interactions between measurement and dose for SBP ($F(1.71, 130 = 12.24, p < 0.000)$ and heart rate ($F(2, 130 = 13.01, p. < 0.000)$, and not for DBP

or body temperature. As expected, MDMA significantly elevated SBP and HR when compared with inactive placebo. By the end of the experimental session, SBP after MDM was 33 mm Hg lower than peak values, and HR was 20.47 BPM lower, indicating the return to pre-drug or near pre-drug levels. Analyses of MP-2 Stage 1 cardiovascular and body temperature measures found a main effect of condition for peak and post-drug average SBP, but one-way ANOVA failed to detect any main effect of condition for DBP, heart rate, or body temperature. Because MP-2 did not collect final measurement, the degree to which peak values returned to normal post-drug cannot be assessed in this sample. The addition of a supplemental dose of MDMA did not increase peak values for vital signs measured during experimental sessions.

Table 2a. : Pre-Drug, Peak, and Final SBP and DBP Values Measured During MP-1

Dose administered within session		SBP: Pre-Drug	SBP: Peak	SBP: Final	DBP: Pre-drug	DBP: Peak	DBP: Final
0 mg 16 sessions 8 subjects	Mean (SD)	112.3 (10.8)	127.7 (15.3)	108.8 (13.1)	73.5 (8.4)	84.6 (10.4)	69.4 (10.4)
	Peak	136.5	157.0	133.0	87.5	102.0	89.0
125 mg 25 sessions 14 subjects	Mean (SD)	111.9 (11.7)	144.7 (18.3)	112.5 (9.3)	72.2 (8.8)	88.6 (11.0)	71.1 (6.7)
	Peak	145.5	189.0	126.0	93.5	113.0	87.0
187.5 mg 26 sessions 10 subjects	Mean (SD)	122.6 (9.9)	151.0 (15.9)	116.7 (10.8)	79.7 (6.4)	93.7 (7.8)	76.2 (6.8)
	Peak	143.5	181.0	141.0	94.0	103.0	88.0

Table 2b. Pre-Drug, Peak, and Final HR and BT (C°) Values Measured During MP-1

Dose administered within session		HR: Pre-drug	HR: Peak	HR: Final	BT: Pre-drug	BT: Peak	BT: Final
0 mg 16 sessions 8 subjects	Mean (SD)	68.2 (10.2)	82.5 (9.6)	71.4 (8.4)	97.5 (0.9)	98.4 (0.6)	97.8 (0.6)
	Peak	91.0	107.0	89.0	99.0	99.6	98.6
125 mg 25 sessions 14 subjects	Mean (SD)	73.3 (11.5)	102.8 (15.0)	82.7 (10.0)	97.6 (0.7)	98.9 (0.5)	98.0 (0.7)
	Peak	99.5	135.0	104.0	99.6	100.0	99.4
187.5 mg 26 sessions 10 subjects	Mean (SD)	74.2 (13.0)	103.7 (19.1)	82.9 (15.7)	97.4 (0.9)	98.6 (0.9)	98.0 (0.7)
	Peak	95.0	140.0	119.0	99.1	100.1	99.3

Table 2c. Pre-Drug, Peak, and Final SBP and DBP Values Measured During MP-2

Dose administered within session		SBP: Pre-drug	SBP: Peak	SBP: Final	DBP: Pre-drug	DBP: Peak	DBP: Final
37.5 mg 13 sessions 5 subjects	Mean (SD)	119.5 (4.6)	131.3 (7.3)	115.9 (7.0)	76.3 (4.0)	84.8 (4.8)	74.5 (3.8)
	Peak	126	144	127	84	92	81
125 mg 3 sessions 2 subjects	Mean (SD)	142.0 (12.3)	181.3 (15.3)	155.3 (11.7)	90.3 (6.6)	110.3 (10.1)	95.7 (7.8)
	Peak	151	193	164	98	121	102
187.5 mg 36 sessions 12 subjects	Mean (SD)	129.9 (16.1)	154.4 (19.4)	135.4 (16.3)	80.0 (8.8)	92.8 (10.2)	81.4 (9.3)
	Peak	177	200	168	101	114	100
212.5 mg 2 sessions 2 subjects	Mean (SD)	132.0 (17.0)	170.5 (20.5)	148.5 (17.7)	83.0 (9.9)	103.5 (6.4)	87.5 (12.0)
	Peak	144	185	161	90	108	96
225 mg 2 sessions 2 subjects	Mean (SD)	124.0 (31.1)	142.5 (20.5)	133.5 (23.3)	74.5 (20.5)	87.0 (12.7)	76.5 (13.4)
	Peak	146	157	150	89	96	86

Table 2d. Pre-Drug, Peak, and Final HR and BT (C°) Values Measured During MP-2

Dose administered within session		HR: Pre-Drug	HR: Peak	HR: Final	BT: Pre-Drug	BT: Peak	BT: Final
37.5 mg 13 sessions 5 subjects	Mean (SD)	76.1 (9.8)	90.8 (18.1)	76.0 (10.9)	36.6 (0.2)	37.6 (0.5)	37.2 (0.4)
	Peak	94	124	90	37.1	38.5	38.00
125 mg 3 sessions 2 subjects	Mean (SD)	79.3 (2.9)	88.7 (15.3)	78.3 (10.6)	36.7 (0.5)	37.3 (0.2)	37.1 (0.2)
	Peak	81	98	88	37.1	37.5	37.30
187.5 mg 36 sessions 12 subjects	Mean (SD)	80.8 (10.4)	105.3 (15.3)	89.0 (12.2)	36.5 (0.4)	37.6 (0.6)	37.2 (0.4)
	Peak	109	144	116	37.6	38.7	38.40
212.5 mg 2 sessions 2 subjects	Mean (SD)	76.0 (1.4)	107.5 (0.7)	96.0 (4.2)	36.7 (0.1)	37.6 (0.4)	37.3 (0.6)
	Peak	77	108	99	36.7	37.9	37.68
225 mg 2 sessions 2 subjects	Mean (SD)	82.5 (19.1)	104.0 (29.7)	93.0 (26.9)	36.7 (0.1)	37.9 (0.5)	37.4 (0.2)
	Peak	96	125	112	36.7	38.2	37.54

8.1.2. Psychological Effects

Psychological distress of participants was assessed periodically throughout experimental sessions in both studies with the single-item, seven-point Subjective Units of Distress (SUD). In both studies, there was no significant difference in SUD scores between MDMA and placebo conditions. In MP-1, an analysis comparing pre-drug average, peak and final post-drug SUD ratings made by participants receiving MDMA versus placebo across Stage 1 and Stage 2 failed to find statistically significant differences in SUD scores. The interaction between dose given (placebo, MDMA) and pre-drug, peak and post-drug SUD was $F(2, 130) = 1.84$, p. = 0.164, and there was no main effect of dose (MDMA or placebo), $F(1, 65) = 1.16$, $p > 0.05$ (p. = 0.29). MDMA did not elevate psychological distress in participants with PTSD to a greater degree than for participants given placebo.

Table 3: Table : Subjective Units of Distress Measured in MP-1

	Dose given	Mean	Std. Dev.	N
Pre-drug	Placebo	3.72	1.97	16
	MDMA	3.05	1.81	51
	Total	3.21	1.85	67
Peak	Placebo	5.19	1.56	16
	MDMA	4.55	1.88	51
	Total	4.70	1.82	67
Final	Placebo	1.69	0.60	16
	MDMA	1.82	1.01	51
	Total	1.79	0.93	67

8.1.3. Expected Adverse Events

Spontaneously reported expected adverse events were collected during the day of each experimental session and for seven days after each session. The list of commonly expected adverse events was derived from the literature (see Table 1). Severity of spontaneously reported reactions were collected on the day of each experimental session and for up to seven days after the session through telephone or face to face contact, with severity rated on a three-point scale. The investigators collected information on duration of reaction for any reaction reported on the day of an experimental session. Anxiety, fatigue, tight jaw, headache, insomnia and lack of appetite were commonly listed during experimental sessions. Anxiety and fatigue were reported at near equal levels by participants given inactive or active placebo and MDMA, while reports of tight jaw were far more frequent in people who received a full dose of MDMA than people who received placebo. Feeling cold, while reported in only 38% of 35 people given a full dose of MDMA, was reported markedly less often in people given inactive or active placebo (19% and 15% respectively). Other less frequently reported reactions that appeared to occur more often in people given at least 125 mg MDMA included impaired gait or balance, impaired concentration and restlessness.

Table 4: Expected Adverse Events Reported for Studies MP-1 and MP-2

Study	**MP1**		**MP2**			**Total**			
MDMA Initial Dose (mg)	**0**	**125**	**25**	**125**	**150**	**0**	**25**	**125**	**150**
Number of Subjects	**8**	**22**	**5**	**13**	**3**	**8**	**5**	**35**	**3**
Number of Sessions	**16**	**51**	**13**	**39**	**4**	**16**	**13**	**90**	**4**
Psychiatric									
Anxiety	14(88%)	48(94%)	4(31%)	20(51%)	1(25%)	14(88%)	4(31%)	67(74%)	1(25%)
Low mood	8(50%)	16(31%)	7(54%)	20(51%)	1(25%)	8(50%)	7(54%)	35(39%)	1(25%)
Insomnia	12(75%)	32(63%)	9(69%)	24(62%)	3(75%)	12(75%)	9(69%)	55(61%)	3(75%)
Restlessness	2(13%)	10(20%)	0	17(44%)	1(25%)	2(13%)	0	24(27%)	1(25%)
Disturbance in attention	2(13%)	12(24%)	0	13(33%)	0	2(13%)	0	25(28%)	0
Drowsiness	3(19%)	4(8%)	1(8%)	3(8%)	0	3(19%)	1(8%)	7(8%)	0
Private Worries	2(13%)	6(12%)	3(23%)	10(26%)	0	2(13%)	3(23%)	15(17%)	0
Nervous System									
Headache	10(63%)	29(57%)	5(38%)	15(38%)	1(25%)	10(63%)	5(38%)	46(51%)	1(25%)
Dizziness	2(13%)	21(41%)	4(31%)	12(31%)	3(75%)	2(13%)	4(31%)	33(37%)	3(75%)
Gastrointestinal									
Nausea	4(25%)	25(49%)	3(23%)	11(28%)	1(25%)	4(25%)	3(23%)	35(39%)	1(25%)
General									
Fatigue	14(88%)	44(86%)	7(54%)	27(69%)	3(75%)	14(88%)	7(54%)	69(77%)	3(75%)
Dry Mouth	0	13(25%)	0	7(18%)	1(25%)	0	0	20(22%)	1(25%)
Heavy Legs	0	2(4%)	1(8%)	1(3%)	1(25%)	0	1(8%)	3(3%)	1(25%)
Impaired Balance	1(6%)	15(29%)	3(23%)	16(41%)	2(50%)	1(6%)	3(23%)	29(32%)	2(50%)
Irritability	8(50%)	18(35%)	1(8%)	9(23%)	0	8(50%)	1(8%)	26(29%)	0
Needs More Sleep	2(13%)	11(22%)	2(15%)	4(10%)	2(50%)	2(13%)	2(15%)	15(17%)	2(50%)
Nystagmus	0	8(16%)	0	4(10%)	1(25%)	0	0	12(13%)	1(25%)
Parasthesia	0	4(8%)	0	2(5%)	1(25%)	0	0	6(7%)	1(25%)
Perspiration	2(13%)	13(25%)	0	6(15%)	1(25%)	2(13%)	0	18(20%)	1(25%)
Feeling Cold	3(19%)	24(47%)	2(15%)	10(26%)	0	3(19%)	2(15%)	34(38%)	0
Thirstiness	1(6%)	7(14%)	0	10(26%)	0	1(6%)	0	17(19%)	0
Feeling Weak	1(6%)	10(20%)	0	5(13%)	1(25%)	1(6%)	0	15(17%)	1(25%)
Musculoskeletal & Connective Tissue									
Muscle tension	3(19%)	42(82%)	1(8%)	16(41%)	1(25%)	3(19%)	1(8%)	56(62%)	1(25%)
Metabolism and Nutrition									
Lack of appetite	1(6%)	33(65%)	6(46%)	17(44%)	1(25%)	1(6%)	6(46%)	43(48%)	1(25%)

8.1.4. Unexpected Adverse Events

One hundred eighty-six adverse events were reported as occurring during studies MP-1 and MP-2. A hundred and twenty-five unexpected adverse events were reported during study MP-1 and 61 unexpected AEs were reported during study MP2. This includes events that occurred prior to administration of medication but after study enrollment. The majority of these events were deemed unrelated (44% of 186 reported, or 81 events) and 34% (63%) were deemed to be possibly related. Twenty-three per cent (42 of 186) were rated as probably related. Since relationship was assessed when the investigator was blinded during Study MP1, some unexpected AEs that were deemed related to the study drug occurred in people given inactive placebo. The greatest number of AEs was reported in 29 of 35 people receiving a full dose (125 mg, with or without supplemental dose) (139 of 186). Fourteen AEs occurred in three of five people given 25 mg MDMA and 33 occurred in all eight people given placebo. Information on the number of unexpected AEs, relatedness, severity and AE outcome can be found in Tables 5a to 5c, below.

Table 5a. Presence and Frequency of Unexpected AEs in Studies MP-1 and MP-2

	Placebo	**25 mg**	**125 mg**	**Total**
Number of Subjects given dose	8	5#	35#**	
Any AEs	33	14	139	186
% of Unexpected AEs	18%	8%	75%	100%
At Least Possibly Related AEs	24*	4	77	105
% of all AEs within Dose	73%	29%	55%	100%
% of all Unexpected AEs	13%	2%	41%	56%
Serious AEs	0	0	4	4
% of all AEs within dose	0%	0%	3%	2%
% of all Unexpected AEs	0%	0%	2%	2%
At Least Possibly Related SAEs	0	0	0	0

*Relatedness rated while blinded
#Subjects withdrew prior to all three sessions, including 1 at 25 mg and three at 125 mg.
** Includes 24 at Stage 1 and 11 placebo or active placebo subjects at Stage 2
Combined table for MP1 and MP2

The intensity of most unexpected adverse events across both studies was rated as moderate. This was true for events in participants who received placebo and 125 mg MDMA. The equal percentage of moderate and severe AEs in participants given active placebo likely reflects the small number of events. Most subjects reported full recovery from these AEs, with 91% of AEs across placebo, 25 and 125 mg MDMA dose.

Table 5b. Severity of unexpected AEs from studies MP1 and MP2 listed by dose

AE Severity	**Placebo**	**%/all Placebo AEs**	**25 mg MDMA**	**%/all 25 mg MDMA AEs**	**125 mg MDMA**	**%/all 125 mg MDMA AEs**	**Total**	**%/all AEs**
Mild	5	15%	4	29%	43	31%	52	28%
Moderate	25	76%	5	36%	87	63%	117	63%
Severe	3	9%	5	36%	9	06%	17	9%
Total	33		14		139		186	

.

Table 5c. All Studies Cumulative Severe Adverse Events
(Based on data received from the sites)

Study	Dose	Subject Number	Adverse Event Diagnosis	Date Last MDMA Admin.	Onset Date	Resolution Date	Serious	Frequency	Action Taken for Study	Action Taken-Treatment	Action Taken Other	Outcome	Relationship to Drug
MP-1	Placebo	0204	Re-experiencing episode	27-Aug-04	28-Aug-04	29-Aug-04	N	Single/ Intermittent	None	Other	Phone contact	Full recovery/ return to baseline	Possibly related
MP-1	Before dosing	0208	Agoraphobia	none	4-Apr-05	9-May-05	N	Continuous	Delayed exper-imental session	Hospital-ization	None	Full recovery/ return to baseline	Not related
MP-1	125mg MDMA	0208	Relapse of major depression	17-Jun-05	29-Jul-05	Ongoing at time of discontinuat ion	N	Continuous	Discon-tinued exper-imental session	Prescription med	Per her doctor	Persists, diminishing	Not related
MP-1	Before dosing	0208	Benzodiazepine withdrawal	none	4-Apr-05	9-May-05	N	Continuous	Delayed exper-imental session	Hospital-ization	None	Full recovery/ return to baseline	Not related
MP-1	125mg MDMA	0209	Sinusitis	22-Jul-05	12-Sep-05	22-Sep-05	N	Single/ Intermittent	None	Prescription med	None	Full recovery/ return to baseline	Not related
MP-1	Placebo	0212	Musculoskeletal chest pain	10-Mar-06	10-Mar-06	10-Mar-06	N	Single/ Intermittent	None	None	None	Full recovery/ return to baseline	Probably related

Unexpected adverse events across both studies were distributed across 19 of the 26 highest-level groups of MedDRA (System Organ Classes, or SOCs), and one that was not placed within any SOC (being the passenger in an automobile accident without reported injury). Most AEs fell under Psychiatric Disorders or General Disorders. From 24 to 43% all AEs fell within the Psychiatric Disorders SOC and included increased anxiety, panic attack, derealization and insomnia. AEs listed under general disorders included fatigue, feeling hot or cold, or body tension. Amount of psychiatric complaints were relatively equal throughout all conditions. It is interesting that increased reports of pain or tightness appeared with relatively greater frequency in people given placebo (30% of people given placebo versus 13% of people given full-dose MDMA; none in people given 25 mg MDMA).

Table 6a. Unexpected AEs by MedDRA System Organ Class listed by dose

MDMA Dose	**0 mg**			**25 mg**			**125 mg**			**Total**	
Body System	**N**	**%/ Dose**	**%/ SOC**	**N**	**%/ Dose**	**%/ SOC**	**N**	**%/ Dose**	**%/ SOC**	**N**	**SOC/ AEs**
No AE (N/subjects)	**0**			**2**	14%	25%	**6**	4%	75%	**8**	4%
Cardiac disorders	**0**			**0**			**2**	1%	100%	**2**	1%
Ear and Labyrinth Disorders	**0**			**1**	7%	100%	**0**			**1**	1%
Eye disorder	**0**			**0**			**4**	3%	100%	**4**	2%
Gastrointestinal Disorders	**2**	6%	10%	**0**			**18**	13%	90%	**20**	11%
General Disorders and Administration Site Conditions	**4**	12%	14%	**4**	29%	14%	**21**	15%	72%	**29**	16%
Infections and Infestations	**3**	9%	23%	**0**			**10**	7%	77%	**13**	7%
Injury, Poisonings and Procedural Complications	**0**			**0**			**1**	1%	100%	**1**	1%
Investigations	**0**			**0**			**2**	1%	100%	**2**	1%
Metabolism and Nutrition Disorders	**0**			**0**			**4**	3%	100%	**4**	2%
Musculoskeletal and Connective Tissue Disorders	**10**	30%	36%	**0**			**18**	13%	64%	**28**	15%
Neoplasms: Benign, Malignant and Unspecified	**0**			**0**			**1**	1%	100%	**1**	1%

MDMA Dose	0 mg			25 mg			125 mg			Total	
Body System	N	%/ Dose	%/ SOC	N	%/ Dose	%/ SOC	N	%/ Dose	%/ SOC	N	SOC/ AEs
Nervous System Disorders	**2**	6%	13%	**2**	14%	13%	**12**	9%	75%	**16**	9%
Psychiatric Disorders	**8**	24%	16%	**6**	43%	12%	**35**	25%	71%	**49**	26%
Renal and urinary disorders	**0**			**0**			**2**			**2**	1%
Reproductive system and breast disorders	**0**			**0**			**1**	1	100%	**1**	1%
Respiratory, Thoracic, and Mediastinal Disorders	**1**	3%	14%	**1**	7%	14%	**5**	4%	71%	**7**	4%
Skin and Subcutaneous Tissue Disorders	**2**	6%	67%	**0**			**1**	1%	33%	**3**	2%
Surgical and medical procedures	**0**			**0**			**1**	1	100%	**1**	1%
Vascular Disorders	**0**			**0**			**1**	1	100%	**1**	1%
Not in established SOC*	**1**	3%	100%	**0**			**0**			**1**	1%
Total of all AEs	**33**			**14**			**139**			**186**	

Full dose includes full dose administered in Stage 1 and Stage 2. A count of "No AEs" could occur in one or both stages.

Seven severe unexpected AEs rated as either possibly or probably related to the study drug occurred during Study MP-1 and Study MP-2. Four of seven events represented a psychiatric complaint or experience, such as a panic attack or an episode of re-experiencing. Full recovery followed all seven events. Upon unblinding it transpired that two of these events had occurred in subjects given inactive placebo; an episode of re-experiencing and musculoskeletal chest pain. The other events were a panic attack after 125 and 62.5 mg in Study MP1, distress after confronting traumatic memories after 25 mg, headache after 25 mg, anxiety and increase in PTSD symptoms after 125 mg and a panic attack after 125 mg. Onset of these events ranged from the day of an experimental session in four cases to seven days after an experimental session in one case. Two of the events from Study MP-2 led to withdrawal from the study for one participant in the active placebo condition and one in the full dose condition. More details about these events can be seen in Table 5c.

Table 6b. Cumulative Frequency of Severe Adverse Events by Relatedness for Studies MP-1 and MP-2

Adverse Event	**MP-1**		**MP-2**		**Total**	
Number of Subjects	23		14		37**	
Number of Experimental Sessions	67		52		119	
Relatedness	PR	NR	PR	NR	PR*	NR*
Psychiatric						
Re-experiencing episode	1				1(2%)	0
Panic Attack	1		1		2(4%)	0
Relapse of major depression		1			0	1(2%)
Anxiety, distress			2		2(4%)	0
Insomnia				2	0	2(4%)
Agoraphobia		1			0	1(2%)
Nervous System						
Headache			1		1(2%)	0
Sciatica		1			0	1(2%)
Gastrointestinal						
Abdominal Cramps/Pain				1	0	1(2%)
General						
Benzodiazepine withdrawal		1			0	1(2%)
Body Pain				1	0	1(2%)
Musculoskeletal & Connective Tissue						
Musculoskeletal chest pain	1				1(2%)	0
Infections and Infestations						
Sinusitis		1			0	1(2%)
Neoplasms						
Brain metastasis				1	0	1(2%)

* Note: PR = Possibly or Probably Related to drug, NR = Not Related to drug, in the opinion of the investigator prior to breaking blind.
** Note: Percentages were calculated based on number of subjects experiencing the AE. Each subject receives between 2 and 6 experimental sessions, depending on the study protocol and their condition assignment
** Based on final data analyzed from the sponsor database listings for completed studies, and preliminary data for ongoing studies

Table 6c. Frequency of Unexpected Adverse Events by Relatedness and by Dosage

Relatedness	**Placebo**	**25 mg MDMA**	**125 mg MDMA**	**Total**	**Relatedness /All AEs**
Unrelated	**9**	**10**	**62**	**81**	**44%**
% out of all Unrelated AEs	11%	12%	77%	100%	
% of AEs at listed dose	27%	71%	45%	44%	
Possibly Related	**21***	**4**	**38**	**63**	**34%**
% of all Possibly Related AEs	33%	6%	60%	100%	
% of all at listed dose	64%	29%	27%	34%	
Probably Related	**3***	**0**	**39**	**42**	**23%**
% of all Probably Related AEs	7%	0	93%	100%	
% of all at listed dose	9%	0	28%	23%	
Total	**33**	**14**	**139**	**186**	**100%**

*Assessment made while blinded

Table 6d. Frequency of Unexpected Adverse Events by Outcome and Condition

Outcome	**0 mg**	**%/ Out come**	**25 mg**	**%/ Out Come**	**125 mg**	**% Out Come**	**Total**	**%/All Unexpec ted AEs**
Full Recovery	30	18%	12	7%	127	75%	169	91%
Persists, Diminishing	1	8%	2	17%	9	75%	12	6%
Persists, the Same	2	67%	0	0%	1	33%	3	2%
Persists, Worsening	0	0%	0	0%	1	100%	1	0.05%
Death	0	0%	0	0%	1	100%	1	0.05%

* Lists number of events and percentage of each dose category that makes up each outcome and for outcome totals, percentage of each outcome within all unexpected adverse events

Four serious adverse events occurred, two in study MP1 and two in study MP2. None of them were drug related. These included broken clavicle, syncope, frontal lobe syndrome, later discerned to be the result of tumor metastasis, and psychiatric hospitalization after self-harm. See table 6e for details of SAEs.

Table 6e. All Studies Cumulative Serious Adverse Events Occurring in Studies MP-1 and MP-2

Study	Dose	Subject Number	Adverse Event Diagnosis	Date Last MDMA Admin.	Onset Date	Resolution Date	Severity	Frequency	Action Taken for Study	Action Taken-Treatment	Action Taken Other	Outcome	Relationship to Drug
MP-1	125mg MDMA	0203	Fractured Clavicle (Auto Accident)	20-Aug-04	31-Aug-04	Continuing	Moderate	Single/ Intermittent	None	Other	Treated in ER	Persists, diminishing	Not related
MP-1	125mg MDMA	0209	Vasovagal Syncope	22-Jul-05	1-Sep-05	1-Sep-05	Moderate	Single/ Intermittent	None	Other	Evaluated in the ER	Full recovery/ return to baseline	Not related
MP-2	125mg MDMA	0101	Brain metastasis (Frontal brain syndrome)	4-Jan-07	31-May-07	18-Jul-07	Severe	Continuous	Removed from study	Hospital-ization	None	Death	Not related
MP-2	Before dosing	0103	Psychiatric hospitalization	none	20-Feb-07	21-Feb-07	Moderate	Single/ Intermittent	None	None	None	Full recovery/ return to baseline	Not related

One death occurred in study MP2. A participant with a previous history of breast cancer assigned to the MDMA condition had a tumor that had metastasized to the brain.

Table 6f. Other significant unexpected adverse events reported during Studies MP-1 and MP-2, including events that led to participant withdrawal

Study	Dose (mg)	Subject	Date of Last Drug Admin	MedDRA Lower Level term	Onset date	Resolution date	Action taken-treatment	Severity	Outcome	Relatedness
MP1	125 mg MDMA	208	17-Jun-2005	Major depression	29-July-2005	None listed	Prescription medication	Severe	Persists, diminishing	Unrelated
MP2	125 mg MDMA	101	24-Nov-06	Panic Attack	26-Nov-06	26-Nov-06	Prescription Medication	Moderate	Full Recovery	Possibly Related
MP2	125 mg MDMA	101	4-Jan-07	Panic Attack	6-Jan-07	6-Jan-07	Prescription Medication	Severe	Full Recovery	Possibly Related
MP2	125 mg MDMA	105	6-Sep-07	Exacerbation of anxiety	6-Sep-07	19-Sep-07	Withdrawn from study due to AE, Prescription Med	Severe	Persists, Diminishing	Probably Related
MP2	37.5 mg MDMA	105	13-Mar-08	Anxiety reaction	13-Mar-08	UNK-Apr-08	Prescription Medication, therapy	Severe	Full Recovery	Possibly Related

8.1.5. Cognitive Effects

An independent rater blind to study condition assessed cognitive performance in all participants at baseline and two months after the second experimental session, using the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) [392], the Paced Auditory Serial Addition and Subtraction Task (PASAT) [393, 394], and the Rey Osterreith figure [395]. The RBANS is a relatively short series of tests used to examine cognitive function. It yields a total score and five sub-scales, including memory, visual spatial, language, attention, and delayed memory, and the PASAT requires participants to add or subtract whole numbers (integers) as they are spoken by a recorded voice. Analyses examined RBANS total scores, percentile scores for PASAT Trial 1 and Trial 2, and X score for the Rey-Osterreith Figure. After establishing that participants in the MDMA and the placebo group performed similarly at baseline using an independent t-test, analyses comparing performance two months after the second experimental session also failed to find either improved or impaired cognitive function participants in the MDMA condition compared with participants in the placebo condition, suggesting that MDMA given during psychotherapy did not adversely affect cognitive function. There was no statistically significant difference between total RBANS scores obtained by participants given MDMA versus those given placebo at two-month follow up, as shown in a comparison of the difference between two-month follow up and baseline total RBANS score $t(1, 19) = 1.32$, $p > 0.05$ ($p = 0.2$). A comparison of the difference between two-month follow up and baseline PASAT scores for both trials failed to find significant differences in performance between participants in the MDMA and the placebo condition, including performance on trial one (t, (1, 19) = -0.211, $p > 0.05$ [p. = 0.83] and trial 2 (t, (1, 18) = 1.2, $p > 0.05$ [p. = 0.244]. The difference between two-month follow up and baseline performance on 30-second delay component of the Rey-Osterreith figure, a measure of delayed visual recall and design reproduction, was compared after MDMA and placebo. The analysis did not detect significant differences between MDMA and placebo participants on 30-second delay performance; 30-second delay raw score t (1, 18 = 1.024, p. > 0.05 [p. = 0.319], 30-second delay T score, t (1, 17)

= 1.115, p > 0.05 [p. = 0.281], and Centile score t (1, 16) = 0.543, p > 0.05 [p. = 0.595]. Taken together, these tests indicate a lack of effect of MDMA upon cognitive function in this study.

Table 8a. Neurocognitive Function - RBANS Total Scores at Baseline and Two Months after the Second Experimental Session

Condition	RBANS Total Score*: Baseline		RBANS Total Score*: 2-month follow up	
	Mean	SD	Mean	SD
Placebo (N = 8)	97.50	12.66	104.88	12.10
MDMA (N = 13)	107.85	13.48	109.00	10.80

*Higher scores indicate greater cognitive function

Table 8b. Cognitive Function - PASAT Trial 1 and Trial 2 Percentile Scores Baseline and Two months Post Follow Up

Condition	PASAT Trial 1 Baseline		PASAT Trial 1 2 month follow up		PASAT Trial 2 Baseline		PASAT Trial 2 2-month follow up	
	Mean	SD	Mean	SD	Mean	SD	Mean	SD
Placebo (N = 8)	30.50	34.45	34.25	32.92	38.24	36.02	46.25	34.01
MDMA (N = 13)*	46.85	29.12	34.46	26.72	59.54	27.56	44.33	24.89

*N = 12 for Trial 2 at two-month follow up, as one person did not complete task.

Table 8c. Table 7c: Cognitive Function Rey Osterreith Completion at Thirty Seconds Delay at Baseline and Two Month Follow-Up

Condition	30 Second Delay: Baseline		30 Second Delay: 2-month follow up	
	Mean	SD	Mean	SD
Placebo (N = 8)	39.50	9.15	42.88	6.22
MDMA (N = 13*)	40.75	12.97	48.17	11.04

*Data for one subject is missing at Baseline

8.2. Efficacy of MDMA-assisted psychotherapy for PTSD

8.2.1. MP-1 Efficacy Results

Analyses of the Clinician Administered PTSD Scale (CAPS) [396, 397] prior to and after two experimental sessions found lower global scores, reflecting fewer or less intense PTSD symptoms, after undergoing experimental psychotherapy sessions with MDMA or placebo. In addition, participants in the MDMA condition experienced a greater decline in PTSD symptoms after undergoing experimental sessions than did participants in the placebo condition. Global CAPS scores declined for all participants over time (overall baseline mean Global CAPS = 79.1 +/- 21.7, and two months after the second experimental session, mean Global CAPS = 38.2 +/-

30.3), indicating a drop of 40.9 points, and a 52% reduction in symptoms. People in the MDMA and placebo conditions began the study with similar CAPS scores, while CAPS scores after experimental sessions were lower for people in the MDMA condition up through two months after the second experimental session (Placebo = 59.1 +/-28.9 versus MDMA, 25.4 +/- 23.95). Placebo participant scores dropped 20.5 points two months after the second experimental session while MDMA participant CAPS scores dropped 53.3 points, or a 26% drop in PTSD symptoms for controls versus a 68% drop in PTSD symptoms for MDMA participants.

Table 8a. Global CAPS Scores for Placebo and MDMA Subjects for MP-1 at T0 (baseline), T1 (**post-Session 1), T2 (post-Session 2), and T3 (2 months post-Session 2)**

Condition	T0*	T1	T2	T3
Placebo (n = 8)				
Mean (SD)	79.6 (22.0)	74.1 (28.5)	66.8 (27.0)	59.1 (28.9)
Range	54-111	21-105	22-103	14-86
MDMA (n = 13)				
Mean (SD)	79.7 (21.0)	36.4 (28.6)	29.2 (18.6)	25.39 (24.0)
Range	43-113	6-107	2-59	0-79
Total (n = 21)				
Mean (SD)	79.7 (20.8)	50.8 (33.6)	43.5 (28.5)	38.2 (30.3)
Range	43-113	6-107	2-103	0-86

*Dropout baseline scores excluded

At baseline, overall Impact of Events Scale scores were similar across both conditions (45.12 +/- 11.84 for placebo, 45 +/- 16.1 for MDMA). As with the CAPS, there was an overall decline in IES scores in participants in both groups two months after a second experimental session (from 45.05 +/- 14.3 at baseline to 212.625 +/- 18.4), or a 232.458-point decline in PTSD symptoms (520% decline). Participants who received MDMA had scores of 15.31 +/- 15.2, representing a 64% decline in PTSD symptoms (28.92 point decline) at two month follow up and participants that received placebo had 32.0 +/- 20.8, representing a 30% decline in symptoms (13.62 point drop). Two months after two sessions of MDMA-assisted psychotherapy, participants who received MDMA had scores of 16.08 +/- 15.6, representing a 64% decline in PTSD symptoms (28.92 point decline) and participants that received placebo had 31.5 +/- 19.3, representing a 30% decline in symptoms (13.62 point drop).

Five participants in the MDMA condition who received an additional session of MDMA-assisted psychotherapy experienced an additional decline in PTSD symptoms, with a global CAPS score of 17, (an 8.5 point decline) below the score seen two months after two sessions of MDMA-assisted psychotherapy under blinded conditions. For participants in the placebo condition, taking part in the open-label study continuation ("Stage 2") produced a Global CAPS of 33.86 (N = 7), a 31.7 point drop in global CAPS (43% decline in PTSD symptoms).

Table 8b. Table 8b: CAPS Scores for Stage 2 (Open-Label) at T3 (Post-Stage 1 Session 3), T4 (2 months post-Stage 2 Session 2), and T5 (2 months post-Stage 3 Session 3)

	T3	T4	T5
N	5	7	4
Mean (SD)	17.0 (15.8)	33.9 (12.8)	25.75 (7.0)
Range	0-36	15-49	19-34

At baseline, overall Impact of Events Scale scores were similar across both conditions (45.12 +/- 11.84 for placebo, 45 +/- 16.1 for MDMA). As with the CAPS, there was an overall decline in IES scores in participants in both groups two months after two experimental sessions (from 45.05 +/- 14.3 at baseline to 22.25 +/- 18.4), or a 22.8-point decline in PTSD symptoms (50% decline). Two months after two sessions of MDMA-assisted psychotherapy, participants who received MDMA had scores of 16.08 +/- 15.6, representing a 64% decline in PTSD symptoms (28.92 point decline) and participants that received placebo had 31.5 +/- 19.3, representing a 30% decline in symptoms (13.62 point drop).

Long-term follow-up data was collected for 20 participants of MP-1 [398]247, which was not statistically different from the mean CAPS score obtained two months after the second stage 1 or stage 2 experimental session (23.924.6; only includes the 17 participants who completed CAPS at LTFU) reported at the 2-month final outcome. The mean IES score at LTFU was 212.194, which was also not statistically different from the mean IES score (13.1919.8) reported at the 2-month final outcome. On the LTFU questionnaire, all subjects reported a benefit from participating in the study, with at least some benefit persisting.

Table 8c. Table 8c: CAPS Scores at LTFU

	Originally MDMA	Originally Placebo	MDMA and Placebo
N	11	6	17
Mean (SD)	25.7 (27.1)	18.7 (7.6)	23.2 (22.1)
Range	0-91	10-31	0-91

At the time of enrollment, 16 of 19 participants reached at LTFU (84%) of subjects were in active psychotherapy, with 12 of 19 (58%) taking psychiatric medications. At LTFU, only 98 of 19 (42%) were in psychotherapy, five of whom were receiving a different type of psychotherapy or psychotherapy from a different therapist. Only one participant not in psychotherapy just prior to the study was attending psychotherapy at LTFU. The percentage of subjects taking psychiatric medication did not change (12/19; 58%), but the mean number of medicines taken fell from 1.7 to 1.3. In addition, none of the medications taken at time of LTFU were for treatment of PTSD.

Table 8d. Table 8d: Medication and Psychotherapy Data Reported at LTFU

	Entry (**n=19**)	LTFU (**n=19**)
# taking meds	12	12
% taking meds	58%	58%
# taking meds for PTSD	7	0
Total # meds	32	23
Avg # meds	1.7	1.3
	Entry (**n=20**)	LTFU (**n=20**)
In therapy	17	9

These findings are suggestive of an effect of MDMA in combination with psychotherapy in reducing PTSD symptoms. The long-term follow-up findings further suggest that the benefits of MDMA-assisted psychotherapy for PTSD are enduring. The greatest problem in study interpretation is that the blind was not very effective, with most participants correctly guessing condition assignment and the investigators correctly guessing in all cases. However, the blind was effective for the independent rater, who was not present during therapy sessions and did not know people's guesses concerning their condition.

8.2.2. MP-2 Efficacy Results

The MP-2 study found results similar to the MP-1 study, but results were less marked. Analyses of global CAPS scores prior to and after three experimental sessions found lower global scores after undergoing experimental psychotherapy sessions with 125 mg MDMA, but not with a 25 mg MDMA active placebo. Global CAPS scores declined over time for the eight participants given a full dose of MDMA (overall baseline mean Global CAPS = 66.4 +/- 13.6, and three weeks after the third experimental session, mean Global CAPS = 50.7 +/- 19.7), indicating a drop of 15.7 points, or a 23.5% decrease in scores. On the other hand, global CAPS scores increased slightly over time for the four participants given an active placebo (overall baseline mean Global CAPS = 63.2 +/- 7.9, and three weeks after the third experimental session, mean Global CAPS = 66.5 +/- 7.5), indicating an increase of 2.3 points, or a 5.2% increase in CAPS scores.

Table 8e. MP-2 Stage 1 Mean CAPS Scores at T0 (Baseline), T1 (3 weeks post-Session 2), and T2 (3 weeks post-Session 3)

Condition assignment		T0	T1	T2
25 mg MDMA	N	5	4	4
	Mean (SD)	64.8 (7.7)	60.0 (6.8)	66.5 (7.6)
	Range	54-72	50-65	57-75
125 mg MDMA	N	9	8	8
	Mean (SD)	68.6 (14.3)	63.0 (17.8)	50.8 (19.7)
	Range	48-86	30-85	14-74
Total	N	14	12	12
	Mean (SD)	67.2 (12.1)	62.0 (14.7)	56.0 (17.9)
	Range	48-86	30-85	14-75

All four active placebo subjects continued to Stage 2 of the study and received open-label full dose MDMA. These subjects experienced a distinct decrease in PTSD symptom severity (at end of Stage 1, mean global CAPS = 66.5 +/- 7.5, and at end of Stage 2, mean global CAPS = 43.7 +/- 14.1).

Table 8f. MP-2 Stage 2 Mean CAPS Scores at T3 (3 weeks post-Session 2), T4 (3 weeks post-Session 3), and T5 (2 months post-Session 3)

Condition assignment		T3	T4	T5
25 mg MDMA (receiving 125 mg in Stage 2)	N	4	4	4
	Mean (SD)	42.5 (25.3)	43.8 (14.1)	36.8 (13.6)
	Range	11-64	25-56	21-50

Twelve participants were assessed 2 months after their final Stage 1 or Stage 2 experimental session, three participants were assessed 6 months after their final Stage 1 or Stage 2 experimental session, and ten participants were assessed 12 months after their final Stage 1 or Stage 2 session. From the 2-month follow-up, after receiving full dose MDMA in either Stage 1 or Stage 2, CAPS Global scores had dropped from an average of 45.0 +/- 16.4 (N=12) to 33.9 +/- 16.8 (N=10) at 12 months after final session. These data suggest that subjects may retain the benefits they experienced three weeks after their third full dose MDMA session, and they may continue to improve after finishing the treatment portion of the study. However, caution should be used in interpreting these results, as many subjects resumed concomitant therapy during the follow-up.

Table 8g. MP-2 Mean CAPS Scores at T6 (2 months follow-up post-Stage 1 or Stage 2), T7 (6 months follow-up), and T8 (12 months follow-up)

Condition assignment		T6	T7	T8
25 mg MDMA	N	4	1	4
	Mean (SD)	36.8 (13.6)	21.0	31.5 (19.2)
	Range	21-50	21	11-54
125 mg MDMA	N	8	2	6
	Mean (SD)	49.1 (16.8)	62.5 (3.5)	35.5 (16.8)
	Range	27-75	61-66	8-54
Total	N	12	3	10
	Mean (SD)	45.0 (16.4)	49.3 (24.7)	33.9 (16.8)
	Range	21-75	21-66	8-54

Though they do not represent as strong an effect of MDMA-assisted psychotherapy upon PTSD symptoms as findings from the MP-1 study, findings from the MP-2 study suggest that MDMA in combination with psychotherapy can reduce PTSD symptoms. The two studies differed with respect to sample size and location and placebo comparator, with MP-1 employing an inactive placebo while MP-2 employed 25 mg MDMA as an active placebo, resulting in somewhat greater success in maintaining the study blind.

Efficacy findings from both studies suggest that people with PTSD could benefit from a course of two or three sessions of MDMA-assisted psychotherapy.

8.3. Marketing Experience

MDMA is currently not approved for marketing anywhere in the world and is a Schedule 1 controlled substance in the U.S.

9. Summary of Data and Guidance for the Investigator

MDMA is a psychoactive compound that some researchers refer to as an entactogen, a compound that affects mood and perception and increasing prosocial feelings. On the basis of narrative reports and several initial studies of MDMA in psychotherapy, the sponsor is investigating use of this compound in combination with psychotherapy for people with PTSD.

Researchers have conducted *in vitro* and *in vivo* studies with MDMA, and clinical trials have been conducted in humans. MDMA is listed in the most restrictive drug schedule in the U.S. (Schedule 1) and is not permitted for use outside of research settings.

9.1. Pharmacology

The pharmacology of MDMA is complex and the chief mechanism behind its therapeutic effects is currently under investigation. Studies in rodents and cell cultures find that MDMA primarily releases serotonin, along with some norepinephrine and even less dopamine. This activity is probably through direct interaction with the transporters for each neurotransmitter. It also acts as an uptake inhibitor of serotonin, norepinephrine, and dopamine. MDMA has very little direct activity on postsynaptic neurotransmitter receptors, and most effects of MDMA are likely due to the direct and indirect effects of monoamine release. Indirect but potentially significant effects of MDMA include the release of the hormones oxytocin and prolactin and transient immunosuppressive and anti-inflammatory effects. Potentially therapeutic effects, such as increased feelings of closeness to others and specific changes in ability to detect facial emotion expression, may be tied to elevated oxytocin after MDMA. One study reported that blocking activation of 5HT2A receptors, but blockage of 5HT1A receptors, attenuated the mood-boosting effects of MDMA. Increased sociability and preclinical studies suggest that the MDMA enantiomers R-(-)-MDMA and S-(+)-MDMA produce different physiological and apparent subjective effects, but comparisons of MDMA enantiomers have not yet occurred in humans.

MDMA shares some effects with psychostimulants, such as increased energy, positive mood, increased blood pressure, heart rate, and it shares other effects with hallucinogenic (psychedelic) compounds, such as changes in perception and thinking, including perceived changes in meaning given to perception, facilitated imagination, and recall. Most previous research in rodents and primates used doses that are higher than those used in humans, and reported increased locomotor activity and signs of serotonin syndrome including flat body posture, an erect tail, forepaw treading and hyperactivity. Studies using approximately human equivalent doses do not report great increases in locomotion.

In humans, MDMA elevates positive mood, and may produce positively or negatively experienced derealization, increased vigor, and anxiety, and slight changes in perception. Recent reports suggest that it may also cause increased feelings of friendliness and sociability. Acutely, MDMA transiently and selectively affects performance on tasks requiring attention and memory. Studies investigating the impact of MDMA on driving suggest that the drug does not strongly alter driving, but impairs some driving-related skills.

MDMA is administered orally in all investigations in humans to date. In humans, onset of effects occurs approximately 30 to 60 minutes after administration, and peak effects occur 75 to 120 minutes after oral administration. Duration of effects lasts three to six hours. Orally administered MDMA has a half-life of seven to nine hours in humans and approximately three hours in monkeys. MDMA is metabolized in the liver by several enzymes. It is likely that active doses of MDMA saturate CYP2D6 function for an extended period, with function normalizing up to ten days post-MDMA. The enzymes CYP1A2, COMT and monoamine oxidase (MAO) may also be involved in the metabolism of MDMA.

Because of its activity as a monoamine releaser, MDMA administration is contraindicated in participants requiring medication with MAO inhibitors. Fatalities have been reported after the combination of MAOIs and MDMA in ecstasy users. Co-administration with an SSRI may eliminate or greatly attenuate the effects of MDMA.

9.2. Risks

Psychotherapists in the US began to use MDMA as an adjunct to psychotherapy in the mid to late 1970s, and a number of narrative accounts exist of therapeutic use prior to its scheduling. MDMA was administered to thousands of people prior to scheduling, and as of November, 2012, it has been administered to approximately 811 people. MDMA has been administered in early open-label studies as well as blinded, placebo controlled Phase 1 studies conducted in the US, Switzerland, Spain, the Netherlands, and the UK, and sponsor-supported studies of MDMA-assisted psychotherapy in the US, Switzerland and Israel. Two sponsor-supported studies have completed investigations of MDMA-assisted psychotherapy in people with PTSD, and another study was designed to investigate MDMA-assisted psychotherapy in people with advanced stage cancer. These studies have demonstrated that MDMA can be safely administered to people with PTSD in a clinical setting.

9.2.1. Risks Associated with Eligibility Screening

Investigators must establish participant eligibility prior to enrollment in trials with MDMA, with eligibility established through medical history, physical examination, vital signs, clinical laboratory tests, stress ECG (if indicated), psychiatric interview, and assessment of relevant psychiatric symptoms. Additional procedures may be used as required, such as exercise tests and ultrasound imaging. If the study is investigating use of MDMA in people with a specific psychiatric condition, then the investigators must also determine whether an individual has the condition. Submitting to a full medical examination may be time consuming and may be distressing or uncomfortable for some.

Prior to enrollment, blood will be drawn as part of screening to assessing eligibility. Temporary discomfort may arise as a result of sampling blood. Participants may experience temporary discomfort at the blood-draw site. There is also a remote possibility of inflammation or infection at the blood-draw site.

Studies of subjective effects of MDMA will employ measures of self-reported mood, experience, and emotional closeness to others. History, presence, and severity of psychiatric disorders are assessed via psychiatric interview and validated instruments such as the Structured Clinical Interview for Diagnosis (SCID) and the CAPS, to assess specific conditions. Because these interviews require individuals to discuss their condition, they may prove upsetting for some. These measures are expected to produce minimal discomfort. Investigators should be experienced in treating the condition under investigation and they should seek to minimize anxiety and distress during these interviews.

9.2.2. Risks Associated with Psychotherapy

Participants enrolled in studies of MDMA-assisted psychotherapy will have a moderate course of psychotherapy sessions with a pair of investigators, one male and one female. During both non-drug and MDMA-assisted psychotherapy sessions, participants will be asked to think about and discuss their experiences, thoughts, and emotions relating to their condition. They may experience intense emotional responses to recalling and speaking about this material. Even in a therapeutic context, thinking about and discussing traumatic experiences, symptoms related to the trauma or the effects of PTSD on life function can produce distress during and immediately after non-drug psychotherapy and experimental sessions. Because psychotherapy is an integral part of the research study design, the potential distress arising from psychotherapy is unavoidable, and is considered a necessary part of the therapeutic process that requires proper facilitation and support from the therapists. Discontinuing PTSD medications and the acute and sub-acute effects of MDMA-assisted psychotherapy can produce shifts in mood and activation, which may increase likelihood of suicidal ideation or behavior.

The sponsor will record all psychotherapy sessions to audio and video, and participants may have access to recordings if they request them. The recordings will be used for further development of a manualized form of MDMA-assisted psychotherapy to be used in future research and to assess investigator adherence to any standardized treatment. Participants will receive information on who will have access to any of their recordings and will have control over any presentation of this material beyond viewing by investigators, trainees, or regulatory agencies. Permission for the recording is part of the informed consent.

9.2.3. Risks of MDMA

The toxicity of MDMA has been investigated in numerous animal and *in vitro* studies published in peer-reviewed journals. In addition, hundreds of published case reports describe adverse events in illicit ecstasy users. Serious MDMA toxicity is rare even in uncontrolled settings, where people take material of unknown identity, potency, and purity, and the many users consuming estimated MDMA doses that are several times higher than those used in the proposed program, without apparent toxicity. Hyperthermia is the most frequently reported adverse effect to occur in this population. In addition to hyperthermic syndromes, other rare adverse events include dysphoria, panic or psychotic response, hepatotoxicity, and hyponatremia. The majority of ecstasy users visiting emergency departments do so because of anxiety or panic. In human clinical trials using MDMA, restrictions in study eligibility are intended to reduce the likelihood of serious adverse events.

Most clinical trials of MDMA employ doses between 75 and 140 mg (1 to 2 mg/kg), comparing these doses with inactive placebo, lower doses of MDMA, or other compounds, such as methylphenidate (Ritalin). Sponsor-supported studies employ a standard full dose of 125 mg, possibly followed by a dose of 62.5 mg 1.5 to 2.5 hours later. A few studies have investigated repeated doses, with doses ranging from 75 and 50 mg to two doses of 100 mg MDMA. Earlier investigations administered the supplemental dose at 2 to 2.5 hours later. This dose has been

compared with doses of 25 mg and 12.5 mg MDMA, with more recent planned studies also employing 30 mg, 40 mg and 75 mg MDMA as comparison doses. All doses are orally administered in opaque capsules. Lactose or a similar inactive material will be used to ensure that all capsules are of equivalent weight and appearance.

Adverse events of MDMA are modest and generally have not been associated with serious discomfort by healthy volunteers in previous studies. Commonly reported adverse events of MDMA include tight jaw, loss of appetite, difficulty concentrating, and impaired gait or balance. Sub-acute effects, including fatigue, feeling anxious or weak, or experiencing low mood are reported up to three days after MDMA administration.

9.2.4. Neurological Risks

Extensive studies in animals suggest that high or repeated doses of MDMA can damage serotonergic axons originating in the brainstem dorsal raphe nuclei, probably as a result of oxidative stress, and this damage is associated with decreases in serotonin, serotonin metabolites, and serotonin transporter site densities. While these findings are consistent across studies, these studies generally overestimated the human equivalence of the doses. Some researchers believe that MDMA is neurotoxic in humans even at doses used in clinical trials. However, studies in very moderate ecstasy users do not report an increase in a biological marker of neuronal injury, and only one of three studies of this marker in humans detected it in heavy users. Three recent retrospective studies found changes in 5HT2A receptors in moderate to heavy ecstasy users. Many retrospective studies have found that ecstasy users have fewer estimated serotonin transporter sites when compared with non-ecstasy users, though some have failed to detect differences. Retrospective studies have also found impaired performance of measures of verbal memory, planning and making decisions, and visual memory. However, some retrospective studies have found little or no differences in cognitive function. A team in the Netherlands has conducted a prospective study of people prior to and after moderate use of ecstasy (in most cases 1-6 tablets). They failed to find changes in serotonin transporter sites or signs of neuronal injury. They found slight changes in cerebral blood flow in the dorsolateral prefrontal cortex but nowhere else. They did find that ecstasy users showed less improvement on a memory task than non-users. It is notable that the study examining SERT sites and regional cerebral blood flow did not employ non-ecstasy user controls, that all participants in the study of cognitive function performed within the normal range, and that one individual examined in the study of cognitive function had reportedly used ecstasy on 30 occasions rather than the limit of 10 occasions set for the other subjects. Data from MP-1, described previously, failed to find differences in neurocognitive performance between people given MDMA and people given inactive placebo. Taken together, these findings fail to confirm serotonergic neurotoxicity after low ecstasy use, but do suggest possible indications of impaired memory.

9.2.5. Cardiovascular Risks

The full dose of 125 mg, alone or followed by a supplemental dose of 62.5 mg 1.5 to 2.5 hours later, is expected to produce significant but transient, self-limited increases in blood pressure and heart rate. Participants enrolled in controlled trials with a single dose of MDMA (approximately 5% per trial) have had elevations above a cut-off of at least 140/90 mmHg, while all participants given a regimen of 100 mg followed by 50 mg two hours later had elevations above 140/90.

Systolic blood pressure above 160 mmHg was detected in approximately 20% to 30% of participants with PTSD, and diastolic blood pressure greater than 110 mmHg occurred in approximately 7% to 10% of participants with PTSD. No medical intervention was needed in studies of healthy humans or people with PTSD. Tables XX to YY show the degree of increase in vital-sign measurements in the investigators' recently completed clinical trial. While maximum peak blood pressure during a given session in some cases rose above the cut-off for making more frequent measures (160 Systolic Blood Pressure (SBP) or 110 Diastolic Blood Pressure (DBP)), no subjects in MP-1 or other clinical trials using MDMA have required any clinical interventions for elevated blood pressure or pulse, and all values returned to normal as the effects of MDMA diminished. The degree of additional blood pressure and pulse elevation is minimal after a second dose of MDMA half the original dose given 1.5 to 2.5 hours after the first dose.

Data from MP-1 demonstrates that elevation in blood pressure and heart rate after the supplemental dose does not exceed elevations seen after the initial dose. Lower doses of MDMA (e.g., 30 or 75 mg) are expected to have lesser effects on blood pressure and heart rate than 125 mg.

Potential complications of elevated blood pressure or heart rate include stroke or myocardial ischemia. These events have not occurred in clinical trials of MDMA. Excluding people with cerebrovascular or cardiovascular disease will reduce the likelihood of risks arising from the cardiovascular effects of MDMA. Investigators conducting trials of MDMA should be prepared to treat elevated blood pressure with medications if necessary and either to provide appropriate care related to these effects or to transport individuals to an emergency department if necessary.

Because of its activity at $5HT_{2B}$ receptors, it is possible that MDMA could stimulate valvular heart disease (VHD). However, studies in ecstasy users indicated that only people reporting average lifetime exposure of 900 tablets had cardiac abnormalities indicative of potential valvular heart disease, and echocardiograms of a small sample of ecstasy users appear normal.

9.2.6. Psychological Risks

Reports of MDMA-assisted psychotherapy conducted prior to the scheduling of MDMA indicate that some people receiving MDMA in a therapeutic context experienced periods of increased anxiety and even panic. Psychological distress from MDMA could arise at any time from the first indications of drug effects until the last effects have dissipated (approximately 3 to 5 hours after drug administration). Anxiety or distress during the session may last for as little as 15 minutes or for as long as 5 hours. In addition, psychological distress could arise following an MDMA session as a result of participants having difficulty integrating their experience after the effects of MDMA have subsided. In previous Phase 1 and Phase 2 studies, these symptoms have been modest and self-limiting, and have responded well to reassurance from the investigator, with occasional use of benzodiazepines for anxiety more than 24 hours after the experimental session. In clinical trials of PTSD treatment, participants are informed that experimental sessions have the intention of confronting and working through traumatic experiences. Hence signs of psychological distress, anxiety, or other unpleasant psychological reactions are to be expected and may be considered an element of the psychotherapeutic process. In Phase I trials

with normal volunteers, mild anxiety and depressed mood are reported by some subjects 1 to 3 days after MDMA administration.

The potential for destabilizing psychological distress will be minimized by:

- excluding people who might be more vulnerable to it (such as people diagnosed with bipolar affective disorder - 1 or with psychotic disorders)
- preparatory non-drug psychotherapy sessions before the experimental session
- creating an atmosphere of trust during the experimental session
- close monitoring
- daily contact with subjects for the period of a week after the experimental session
- providing non-drug integrative psychotherapy sessions
- having subjects remain at the study site for the night of each experimental session to further reduce psychological distress, and having qualified personnel, such as a trained attendant, available during the overnight stay to respond to the needs of the subject.

Attendants will be instructed to contact the investigator upon request or at the appearance of signs of a potential adverse event. Every effort will be made to help subjects resolve difficult symptoms and to arrive at a more comfortable and relaxed state by the conclusion of the session. Such efforts will include empathic listening on the part of the investigators and affect management techniques such as diaphragmatic breathing by subjects.

At the end of any experimental session, if the subject is still severely agitated or experiencing any other severe psychological distress, the following measures will be taken:

1. If the subject is anxious, agitated, and/or in danger of any self-harm or is suicidal at the end of the MDMA session, the investigators will remain with the subject for at least two more hours. During this time, the investigators will employ affect management techniques reviewed during the introductory sessions and will talk with the subject to help him or her gain cognitive perspective of their experience. If this situation should occur during an integrative therapy session, the same approach will be used, and at least one of the investigators will be available to stay with the subject for at least two additional hours.
2. If a subject remains severely anxious, agitated or in danger of self-harm or suicide, or is otherwise psychologically unstable at the end of this two-hour stabilization period, the clinical investigator will decide between the following options:

    a. A psychiatric nurse, therapeutic assistant, or therapist will stay with the subject until the time of his or her appointment with investigators the next day. The investigators will then meet with the subject daily until the period of destabilization has passed.
    b. If a subject experiences severe, persisting emotional distress, such as panic attacks, severe generalized anxiety, or insomnia following an MDMA session, the investigator may prescribe a benzodiazepine or zolpidem as a "rescue medication." Investigators should not prescribe an SSRI, SNRI, MAOI, or any other psychotropic medication in this context. Residual symptoms will be addressed during the frequent follow-

up psychotherapy visits with the investigators.

c. Hospitalization for stabilization. If a subject should become psychotic, arrangements will be made to stabilize and transfer him or her to the study site inpatient unit or the nearest appropriate inpatient psychiatric facility.

Subjects hospitalized after a severe panic reaction will be suspended from further participation in the trial until after recovery or stabilization, at which time the investigator will carefully evaluate the subject's emotional status and decide whether or not the subject may continue the study. For those subjects engaged in an ongoing therapeutic relationship with a psychotherapist or psychiatrist, the subject's outside therapists will be involved in the management of any psychiatric complications.

9.2.7. Risks Related to Body Temperature

Findings from previous Phase 1 trials indicate that MDMA administered in a controlled setting produces only a slight increase in body temperature, and ambient temperature neither increases nor attenuates this slight elevation in humans. Approximately 30% of people with PTSD exhibited an elevation in BT greater than 1 C, but no medical intervention was required in any of these cases. However, hyperthermia has occurred in ecstasy users. Maximum body temperature could rise above normal temperature, as with the maximum peak of 100° Fahrenheit (F), or 37.7 Celsius (C), during the first experimental session in the sponsor's recent Phase 2 trial (n = 23, MDMA and placebo conditions combined). In this study, body temperature returned to normal without treatment other than simply lowering the ambient temperature, which may or may not have been necessary. Investigators should assess body temperature periodically. Sponsor-supported studies have assessed it every 60 to 90 minutes. The investigators must be able to cool body temperature if necessary through removing blankets and layers of clothing, decreasing the ambient temperature and, if necessary, directing a fan toward the subject. Further cooling with ice packs or, if available, a cooling blanket, can be used if these steps do not reduce body temperature. Subjects with signs or symptoms of heat stroke will be transferred to the nearest hospital for treatment.

9.2.8. Immunological Risks

Humans exhibit transient immunological changes after a dose of 100 mg, including reduced numbers of CD4 cells, increased numbers of NK cells, and an increase in levels of immunosuppressive and anti-inflammatory cytokines compared with levels of pro-inflammatory and immunostimulating cytokines. In several respects, these effects are similar to those that occur with other psychoactive substances and are not unique to MDMA. Immunological effects last for approximately 24 hours after administration, and most arise indirectly from serotonin release. The significance of these immunological effects remains unclear. Previous reports did not show increases in infections after MDMA and data from the study of MDMA-assisted psychotherapy has reported only instances of infection (upper respiratory) within seven days of MDMA administration. Based on results from trials conducted by the Sponsor, the impact of these effects is expected to be modest. The investigators may exclude participants that might face additional risks from immunosuppression.

9.2.9. Reproductive and Developmental Risks

Risks posed to pregnant women by MDMA are not known. One of two studies of ecstasy users suggests that use of ecstasy and other drugs during pregnancy may be associated with some abnormalities at birth while the other failed to find this association, and a third study detected a link between degree of self-reported prenatal exposure to ecstasy and delays in infant development. All sponsor-supported trials of MDMA exclude pregnant and lactating women, and women who are able to become pregnant must have a negative pregnancy screen before undergoing each experimental session and must agree to use birth control during the period of the protocol. If any participant becomes pregnant during study participation, the sponsor and clinical investigator will follow the pregnancy to outcome.

9.2.10. Risk of Abuse

Despite its classification as a Schedule 1 drug, an examination of findings in humans and animals suggests that MDMA possesses moderate abuse potential that is higher than that reported for "classic hallucinogens" like psilocybin, but lower than that reported for psychostimulants such as cocaine or methamphetamine. Studies assessing prevalence of problematic ecstasy use or dependence suggest that a small percentage of individuals, especially those with prior psychological difficulties, may develop problematic ecstasy use or dependence. In two studies of MDMA-assisted psychotherapy for people with PTSD, only one of 32 participants reported using ecstasy subsequent to study participation, and several subjects volunteered that they would not seek out ecstasy outside of a psychotherapeutic setting. Diversion is not an issue for sponsor-supported studies because MDMA will only be administered under the supervision of the clinical investigator and no take-home doses will be permitted. MDMA will be handled following all regulations pertaining to the handling and dispensing of controlled substances within research studies.

10. Conclusion

Based on the current state of scientific knowledge, the risk for subjects meeting inclusion and exclusion criteria who are exposed to MDMA at doses used in sponsor-supported studies in a clinical setting appear to be manageable. Future studies conducted by the Sponsor are intended to further develop the safety profile of MDMA in the PTSD subject population. MDMA-assisted psychotherapy appears to be a promising treatment method for chronic PTSD, and more clinical trials in larger subject populations are warranted.

11. References

1. Shulgin, A.T., *The background and chemistry of MDMA.* J Psychoactive Drugs, 1986. **18**(4): p. 291-304.
2. Kolbrich, E.A., et al., *Physiological and subjective responses to controlled oral 3,4-methylenedioxymethamphetamine administration.* J Clin Psychopharmacol, 2008. **28**(4): p. 432-40.
3. Cami, J., et al., *Human pharmacology of 3,4-methylenedioxymethamphetamine ("ecstasy"): psychomotor performance and subjective effects.* J Clin Psychopharmacol, 2000. **20**(4): p. 455-66.
4. Mas, M., et al., *Cardiovascular and neuroendocrine effects and pharmacokinetics of 3, 4-methylenedioxymethamphetamine in humans.* J Pharmacol Exp Ther, 1999. **290**(1): p. 136-45.
5. Harris, D.S., et al., *Subjective and hormonal effects of 3,4-methylenedioxymethamphetamine (MDMA) in humans.* Psychopharmacology (Berl), 2002. **162**(4): p. 396-405.
6. Liechti, M.E., A. Gamma, and F.X. Vollenweider, *Gender differences in the subjective effects of MDMA.* Psychopharmacology (Berl), 2001. **154**(2): p. 161-8.
7. Tancer, M. and C.E. Johanson, *Reinforcing, subjective, and physiological effects of MDMA in humans: a comparison with d-amphetamine and mCPP.* Drug Alcohol Depend, 2003. **72**(1): p. 33-44.
8. Vollenweider, F.X., et al., *Psychological and cardiovascular effects and short-term sequelae of MDMA ("ecstasy") in MDMA-naive healthy volunteers.* Neuropsychopharmacology, 1998. **19**(4): p. 241-51.
9. Downing, J., *The psychological and physiological effects of MDMA on normal volunteers.* J Psychoactive Drugs, 1986. **18**(4): p. 335-40.
10. Lester, S.J., et al., *Cardiovascular effects of 3,4-methylenedioxymethamphetamine. A double-blind, placebo-controlled trial.* Ann Intern Med, 2000. **133**(12): p. 969-73.
11. Bedi, G., et al., *Effects of MDMA on sociability and neural response to social threat and social reward.* Psychopharmacology (Berl), 2009. **207**(1): p. 73-83.
12. Kirkpatrick, M.G., et al., *A direct comparison of the behavioral and physiological effects of methamphetamine and 3,4-methylenedioxymethamphetamine (MDMA) in humans.* Psychopharmacology (Berl), 2012. **219**(1): p. 109-22.
13. Grob, C.S., et al., *Psychobiologic effects of 3,4-methylenedioxymethamphetamine in humans: methodological considerations and preliminary observations.* Behav Brain Res, 1996. **73**(1-2): p. 103-7.
14. Beck, J. and M. Rosenbaum, *In Pursuit of Ecstasy: The MDMA Experience*. 1994, Albany, NY: SUNY Press.
15. Solowij, N., W. Hall, and N. Lee, *Recreational MDMA use in Sydney: a profile of 'Ecstacy' users and their experiences with the drug.* Br J Addict, 1992. **87**(8): p. 1161-72.
16. Carlson, R.G., et al., *Drug use practices among MDMA/ecstasy users in Ohio: a latent class analysis.* Drug Alcohol Depend, 2005. **79**(2): p. 167-79.
17. Sumnall, H.R., J.C. Cole, and L. Jerome, *The varieties of ecstatic experience: an exploration of the subjective experiences of ecstasy.* J Psychopharmacol, 2006. **20**(5): p. 670-82.

18. Cole, J.C. and H.R. Sumnall, *Altered states: the clinical effects of Ecstasy.* Pharmacol Ther, 2003. **98**(1): p. 35-58.
19. Baggott, M.J., *Preventing problems in Ecstasy users: reduce use to reduce harm.* J Psychoactive Drugs, 2002. **34**(2): p. 145-62.
20. Gore, S.M., *Fatal uncertainty: death-rate from use of ecstasy or heroin.* Lancet, 1999. **354**(9186): p. 1265-6.
21. Mithoefer, M.C., et al., *The safety and efficacy of {+/-}3,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot study.* J Psychopharmacol, 2011. **25**(4): p. 439-52.
22. Mithoefer, M., et al., *Data on long-term follow-up to study of safety and efficacy of MDMA-assisted psychotherapy in individuals with PTSD.* Unpublished.
23. Oehen, P., Traber, R., Widmer, V., Schnyder, U., *Pilot study of MDMA-assisted psychotherapy for treatment-resistant PTSD.* unpublished.
24. Bouso, J.C., et al., *MDMA-assisted psychotherapy using low doses in a small sample of women with chronic posttraumatic stress disorder.* J Psychoactive Drugs, 2008. **40**(3): p. 225-36.
25. Freudenmann, R.W., F. Oxler, and S. Bernschneider-Reif, *The origin of MDMA (ecstasy) revisited: the true story reconstructed from the original documents.* Addiction, 2006. **101**(9): p. 1241-5.
26. Shulgin, A. and A. Shulgin, *Pihkal: A Chemical Love Story.* 1st ed. 1991, Berkeley, CA: Transform Press. 1-978.
27. Anderson, G.M.d., et al., *Absolute configuration and psychotomimetic activity.* NIDA Res Monogr, 1978. **22**: p. 8-15.
28. Shulgin, A.T. and D.E. Nichols, *Characterization of three new psychotomimetics*, in *The Pharmacology of Hallucinogens*, R.C. Stillman and R.E. Willette, Editors. 1978, Pergamon: New York.
29. Adamson, S., *Through the gateway of the heart: Accounts of experiences With MDMA and other empathogenic substances.* 1985, San Francisco CA: Four Trees Publications.
30. Grinspoon, L. and J.B. Bakalar, *Can drugs be used to enhance the psychotherapeutic process?* Am J Psychother, 1986. **40**(3): p. 393-404.
31. Nichols, D.E., *Differences between the mechanism of action of MDMA, MBDB, and the classic hallucinogens. Identification of a new therapeutic class: entactogens.* J Psychoactive Drugs, 1986. **18**(4): p. 305-13.
32. Greer, G. and R.J. Strassman, *Information on "Ecstasy".* Am J Psychiatry, 1985. **142**(11): p. 1391.
33. Greer, G.R. and R. Tolbert, *A method of conducting therapeutic sessions with MDMA.* J Psychoactive Drugs, 1998. **30**(4): p. 371-379.
34. Metzner, R. and S. Adamson, *Using MDMA in healing, psychotherapy and spiritual practice*, in *Ecstasy, A Complete Guide: A Comprehensive Look at the Risks and Benefits of MDMA.*, J. Holland, Editor. 2001, Inner Traditions: Rochester VT. p. 182-207.
35. Greer, G. and R. Tolbert, *The therapeutic use of MDMA.*, in *Ecstasy: The clinical, pharmacological and neurotoxicological effects of the drug MDMA.*, S.J. Peroutka, Editor. 1990, Kluver Academic: Boston, MA. p. 21-35.
36. Carlson, R.G., et al., *MDMA/Ecstasy use among young people in Ohio: perceived risk and barriers to intervention.* J Psychoactive Drugs, 2004. **36**(2): p. 181-9.
37. Drug_Enforcement_Administration, *Scheduling of Controlled Substances: Scheduling of*

3,4-methylenedioxymethamphetamine (MDMA) into Schedule 1 of the Controlled Substances Act: Remand, DEA, Editor. 1988, Federal Register: Washington, DC. p. 5156-5160.

38. Lawn, J.C., *On the Matter of MDMA Scheduling*, in *Docket No. 84-48*, Drug_Enforcement_Administration, Editor. 1986: Washington, DC.
39. Seiden, L.S. and K.E. Sabol, *Methamphetamine and methylenedioxymethamphetamine neurotoxicity: possible mechanisms of cell destruction.* NIDA Res Monogr, 1996. **163**: p. 251-76.
40. Rogers, G., et al., *The harmful health effects of recreational ecstasy: a systematic review of observational evidence.* Health Technol Assess, 2009. **13**(6): p. iii-iv, ix-xii, 1-315.
41. Henry, J.A., K.J. Jeffreys, and S. Dawling, *Toxicity and deaths from 3,4-methylenedioxymethamphetamine ("ecstasy").* Lancet, 1992. **340**(8816): p. 384-7.
42. Cohen, R.S. and J. Cocores, *Neuropsychiatric manifestations following the use of 3,4-methylenedioxymethamphetamine (MDMA: "Ecstasy").* Prog Neuropsychopharmacol Biol Psychiatry, 1997. **21**(4): p. 727-34.
43. Williamson, S., et al., *Adverse effects of stimulant drugs in a community sample of drug users.* Drug Alcohol Depend, 1997. **44**(2-3): p. 87-94.
44. Krystal, J.H., et al., *Chronic 3,4-methylenedioxymethamphetamine (MDMA) use: effects on mood and neuropsychological function?* Am J Drug Alcohol Abuse, 1992. **18**(3): p. 331-41.
45. McCann, U.D., et al., *Serotonin neurotoxicity after (+/-)3,4-methylenedioxymethamphetamine (MDMA; "Ecstasy"): a controlled study in humans.* Neuropsychopharmacology, 1994. **10**(2): p. 129-38.
46. McCann, U.D., et al., *Cognitive performance in (+/-) 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy") users: a controlled study.* Psychopharmacology (Berl), 1999. **143**(4): p. 417-25.
47. Parrott, A.C. and J. Lasky, *Ecstasy (MDMA) effects upon mood and cognition: before, during and after a Saturday night dance.* Psychopharmacology (Berl), 1998. **139**(3): p. 261-8.
48. Ricaurte, G.A., et al., *Toxicodynamics and long-term toxicity of the recreational drug, 3, 4-methylenedioxymethamphetamine (MDMA, 'Ecstasy').* Toxicol Lett, 2000. **112-113**: p. 143-6.
49. Baumann, M.H., et al., *Effects of dose and route of administration on pharmacokinetics of (+ or -)-3,4-methylenedioxymethamphetamine in the rat.* Drug Metab Dispos, 2009. **37**(11): p. 2163-70.
50. Biezonski, D.K. and J.S. Meyer, *The Nature of 3, 4-Methylenedioxymethamphetamine (MDMA)-Induced Serotonergic Dysfunction: Evidence for and Against the Neurodegeneration Hypothesis.* Curr Neuropharmacol, 2011. **9**(1): p. 84-90.
51. Gouzoulis-Mayfrank, E. and J. Daumann, *The confounding problem of polydrug use in recreational ecstasy/MDMA users: a brief overview.* J Psychopharmacol, 2006. **20**(2): p. 188-93.
52. Bouso, J.C., *MDMA/PTSD research in Spain: An update.* MAPS Bulletin, 2003. **13**(1): p. 7-8.
53. Bedi, G., D. Hyman, and H. de Wit, *Is ecstasy an "empathogen"? Effects of +/-3,4-methylenedioxymethamphetamine on prosocial feelings and identification of emotional states in others.* Biol Psychiatry, 2010. **68**(12): p. 1134-40.
54. Dumont, G.J., et al., *Increased oxytocin concentrations and prosocial feelings in humans*

after ecstasy (3,4-methylenedioxymethamphetamine) administration. Soc Neurosci, 2009. **4**(4): p. 359-66.

55. Farre, M., et al., *Pharmacological interaction between 3,4-methylenedioxymethamphetamine (ecstasy) and paroxetine: pharmacological effects and pharmacokinetics.* J Pharmacol Exp Ther, 2007. **323**(3): p. 954-62.
56. Hysek, C.M., G. Domes, and M.E. Liechti, *MDMA enhances "mind reading" of positive emotions and impairs "mind reading" of negative emotions.* Psychopharmacology (Berl), 2012. **222**(2): p. 293-302.
57. van Wel, J.H., et al., *Effects of Acute MDMA Intoxication on Mood and Impulsivity: Role of the 5-HT(2) and 5-HT(1) Receptors.* PLoS One, 2012. **7**(7): p. e40187.
58. Lyon, R.A., R.A. Glennon, and M. Titeler, *3,4-Methylenedioxymethamphetamine (MDMA): stereoselective interactions at brain 5-HT1 and 5-HT2 receptors.* Psychopharmacology (Berl), 1986. **88**(4): p. 525-6.
59. Fantegrossi, W.E., et al., *Discriminative stimulus effects of MDMA and its enantiomers in mice: pharmacokinetic considerations.* J Pharmacol Exp Ther, 2009.
60. Yarosh, H.L., et al., *MDMA-like behavioral effects of N-substituted piperazines in the mouse.* Pharmacol Biochem Behav, 2007. **88**(1): p. 18-27.
61. Fantegrossi, W.E., et al., *3,4-Methylenedioxymethamphetamine (MDMA, "ecstasy") and its stereoisomers as reinforcers in rhesus monkeys: serotonergic involvement.* Psychopharmacology (Berl), 2002. **161**(4): p. 356-64.
62. McClung, J., W. Fantegrossi, and L.L. Howell, *Reinstatement of extinguished amphetamine self-administration by 3,4-methylenedioxymethamphetamine (MDMA) and its enantiomers in rhesus monkeys.* Psychopharmacology (Berl), 2010. **210**(1): p. 75-83.
63. Murnane, K.S., et al., *Endocrine and neurochemical effects of 3,4-methylenedioxymethamphetamine and its stereoisomers in rhesus monkeys.* J Pharmacol Exp Ther, 2010. **334**(2): p. 642-50.
64. Murnane, K.S., et al., *The neuropharmacology of prolactin secretion elicited by 3,4-methylenedioxymethamphetamine ("ecstasy"): a concurrent microdialysis and plasma analysis study.* Horm Behav, 2012. **61**(2): p. 181-90.
65. Spitzer, M., et al., *Enantio-selective cognitive and brain activation effects of N-ethyl-3,4-methylenedioxyamphetamine in humans.* Neuropharmacology, 2001. **41**(2): p. 263-71.
66. Acquas, E., et al., *Differential effects of intravenous R,S-(+/-)-3,4-methylenedioxymethamphetamine (MDMA, Ecstasy) and its S(+)- and R(-)-enantiomers on dopamine transmission and extracellular signal regulated kinase phosphorylation (pERK) in the rat nucleus accumbens shell and core.* J Neurochem, 2007. **102**(1): p. 121-32.
67. Nichols, D.E., *Chromatographic Purity Of 3,4-Methylenedioxymethamphetamine Hydrochloride (MDMA Hydrochloride), Lot 5810-09.* 2006, Purdue University: Lafayette IN. p. 1-6.
68. Battaglia, G., et al., *Pharmacologic profile of MDMA (3,4-methylenedioxymethamphetamine) at various brain recognition sites.* Eur J Pharmacol, 1988. **149**(1-2): p. 159-63.
69. Setola, V., et al., *3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy") induces fenfluramine-like proliferative actions on human cardiac valvular interstitial cells in vitro.* Mol Pharmacol, 2003. **63**(6): p. 1223-9.
70. Jones, D.C., S.S. Lau, and T.J. Monks, *Thioether metabolites of 3,4-methylenedioxyamphetamine and 3,4-methylenedioxymethamphetamine inhibit human*

serotonin transporter (hSERT) function and simultaneously stimulate dopamine uptake into hSERT-expressing SK-N-MC cells. J Pharmacol Exp Ther, 2004. **311**(1): p. 298-306.

71. PDSP, *MDMA receptor binding profiles from Psychoactive Drug Screening Program Database Contract # NO1MH32004 (NIMH PDSP), with data accessed between November 12 and November 14, 2007.* 2007, National Institute of Mental Health.
72. Mlinar, B. and R. Corradetti, *Endogenous 5-HT, released by MDMA through serotonin transporter- and secretory vesicle-dependent mechanisms, reduces hippocampal excitatory synaptic transmission by preferential activation of 5-HT1B receptors located on CA1 pyramidal neurons.* Eur J Neurosci, 2003. **18**(6): p. 1559-71.
73. Verrico, C.D., G.M. Miller, and B.K. Madras, *MDMA (Ecstasy) and human dopamine, norepinephrine, and serotonin transporters: implications for MDMA-induced neurotoxicity and treatment.* Psychopharmacology (Berl), 2007. **189**(4): p. 489-503.
74. Han, D.D. and H.H. Gu, *Comparison of the monoamine transporters from human and mouse in their sensitivities to psychostimulant drugs.* BMC Pharmacol, 2006. **6**: p. 6.
75. Johnson, M.P., A.J. Hoffman, and D.E. Nichols, *Effects of the enantiomers of MDA, MDMA and related analogues on [3H]serotonin and [3H]dopamine release from superfused rat brain slices.* Eur J Pharmacol, 1986. **132**(2-3): p. 269-76.
76. Cole, J.C. and H.R. Sumnall, *The pre-clinical behavioural pharmacology of 3,4-methylenedioxymethamphetamine (MDMA).* Neurosci Biobehav Rev, 2003. **27**(3): p. 199-217.
77. Rudnick, G. and S.C. Wall, *The molecular mechanism of "ecstasy" [3,4-methylenedioxy-methamphetamine (MDMA)]: serotonin transporters are targets for MDMA-induced serotonin release.* Proc Natl Acad Sci U S A, 1992. **89**(5): p. 1817-21.
78. Bradbury, S., et al., *Acquisition of MDMA self-administration: pharmacokinetic factors and MDMA-induced serotonin release.* Addict Biol, 2013.
79. Isbister, G.K. and N.A. Buckley, *The pathophysiology of serotonin toxicity in animals and humans: implications for diagnosis and treatment.* Clin Neuropharmacol, 2005. **28**(5): p. 205-14.
80. Gillman, P.K., *Ecstasy, serotonin syndrome and the treatment of hyperpyrexia.* Med J Aust, 1997. **167**(2): p. 109, 111.
81. Mueller, P.D. and W.S. Korey, *Death by "ecstasy": the serotonin syndrome?* Ann Emerg Med, 1998. **32**(3 Pt 1): p. 377-80.
82. Hardman, H.F., C.O. Haavik, and M.H. Seevers, *Relationship of the structure of mescaline and seven analogs to toxicity and behavior in five species of laboratory animals.* Toxicol Appl Pharmacol, 1973. **25**(2): p. 299-309.
83. Baggott, M., L. Jerome, and R. Stuart, *3,4-Methylenedioxymethamphetamine (MDMA); A review of the English-language scientific and medical literature:* , in *First Edition of Investigator's Brochure for MDMA.* 2001, Multidiscplinary Association for Psychedelic Studies.
84. Mechan, A., et al., *Pharmacokinetic profile of single and repeated oral doses of MDMA in squirrel monkeys: relationship to lasting effects on brain serotonin neurons.* Neuropsychopharmacology, 2006. **31**(2): p. 339-50.
85. Wang, X., et al., *(+/-)-3,4-Methylenedioxymethamphetamine administration to rats does not decrease levels of the serotonin transporter protein or alter its distribution between endosomes and the plasma membrane.* J Pharmacol Exp Ther, 2005. **314**(3): p. 1002-12.
86. Mueller, M., et al., *Direct comparison of (+/-) 3,4-methylenedioxymethamphetamine ("ecstasy") disposition and metabolism in squirrel monkeys and humans.* Ther Drug

Monit, 2009. **31**(3): p. 367-73.
87. Mueller, M., et al., *Simultaneous liquid chromatographic-electrospray ionization mass spectrometric quantification of 3,4-methylenedioxymethamphetamine (MDMA, Ecstasy) and its metabolites 3,4-dihydroxymethamphetamine, 4-hydroxy-3-methoxymethamphetamine and 3,4-methylenedioxyamphetamine in squirrel monkey and human plasma after acidic conjugate cleavage.* Forensic Sci Int, 2009. **184**(1-3): p. 64-8.
88. Nair, S.G. and G.A. Gudelsky, *3,4-Methylenedioxymethamphetamine (MDMA) enhances the release of acetylcholine by 5-HT4 and D1 receptor mechanisms in the rat prefrontal cortex.* Synapse, 2005. **58**(4): p. 229-35.
89. Nair, S.G. and G.A. Gudelsky, *3,4-Methylenedioxymethamphetamine enhances the release of acetylcholine in the prefrontal cortex and dorsal hippocampus of the rat.* Psychopharmacology (Berl), 2006. **184**(2): p. 182-9.
90. Giannaccini, G., et al., *Short-term effects of 3,4-methylen-dioxy-metamphetamine (MDMA) on 5-HT(1A) receptors in the rat hippocampus.* Neurochem Int, 2007. **51**(8): p. 496-506.
91. Brunner, D. and R. Hen, *Insights into the neurobiology of impulsive behavior from serotonin receptor knockout mice.* Ann N Y Acad Sci, 1997. **836**: p. 81-105.
92. Graeff, F.G., et al., *Role of 5-HT in stress, anxiety, and depression.* Pharmacol Biochem Behav, 1996. **54**(1): p. 129-41.
93. Glennon, R.A. and R. Young, *MDMA stimulus generalization to the 5-HT(1A) serotonin agonist 8-hydroxy-2- (di-n-propylamino)tetralin.* 2000. **66**(3): p. 483-488.
94. Glennon, R.A., et al., *N-Methyl-1-(4-methoxyphenyl)-2-aminopropane (PMMA) and N-Methyl-1-(3,4-methylenedioxyphenyl)-2-aminopropane (MDMA) produce non-identical discriminative stimuli in rats.* Pharmacol Biochem Behav, 2007. **86**(3): p. 477-84.
95. Schechter, M.D., *Discriminative profile of MDMA.* Pharmacol Biochem Behav, 1986. **24**(6): p. 1533-7.
96. Morley, K.C., J.C. Arnold, and I.S. McGregor, *Serotonin (1A) receptor involvement in acute 3,4-methylenedioxymethamphetamine (MDMA) facilitation of social interaction in the rat.* Prog Neuropsychopharmacol Biol Psychiatry, 2005. **29**(5): p. 648-57.
97. Thompson, M.R., et al., *A role for oxytocin and 5-HT(1A) receptors in the prosocial effects of 3,4 methylenedioxymethamphetamine ("ecstasy").* Neuroscience, 2007. **146**(2): p. 509-14.
98. Bankson, M.G. and B.K. Yamamoto, *Serotonin-GABA interactions modulate MDMA-induced mesolimbic dopamine release.* J Neurochem, 2004. **91**(4): p. 852-9.
99. Peng, W., et al., *Synaptotagmin I and IV are differentially regulated in the brain by the recreational drug 3,4-methylenedioxymethamphetamine (MDMA).* Brain Res Mol Brain Res, 2002. **108**(1-2): p. 94-101.
100. Pompei, P., et al., *Preprotachykinin A gene expression after administration of 3,4-methylene dioxymethamphetamine (Ecstasy).* Eur J Pharmacol, 2002. **450**(3): p. 245.
101. Sprague, J.E., et al. *Effects of antisense oligonucleotide alteration of MAO-B gene expression on MDMA-induced serotonergic neurotoxicity.* in *Society for Neuroscience.* 1999. Miami, FL.
102. Thiriet, N., et al., *Analysis of ecstasy (MDMA)-induced transcriptional responses in the rat cortex.* Faseb J, 2002. **16**(14): p. 1887-94.
103. Biezonski, D.K. and J.S. Meyer, *Effects of 3,4-methylenedioxymethamphetamine (MDMA) on serotonin transporter and vesicular monoamine transporter 2 protein and gene expression in rats: implications for MDMA neurotoxicity.* J Neurochem, 2010.

112(4): p. 951-62.

104. Kindlundh-Hogberg, A.M., P. Svenningsson, and H.B. Schioth, *Quantitative mapping shows that serotonin rather than dopamine receptor mRNA expressions are affected after repeated intermittent administration of MDMA in rat brain.* Neuropharmacology, 2006. **51**(4): p. 838-47.
105. Salzmann, J., et al., *Analysis of transcriptional responses in the mouse dorsal striatum following acute 3,4-methylenedioxymethamphetamine (ecstasy): identification of extracellular signal-regulated kinase-controlled genes.* Neuroscience, 2006. **137**(2): p. 473-82.
106. Ferraz de Paula, V., et al., *Methylenedioxymethamphetamine (Ecstasy) Decreases Neutrophil Activity and Alters Leukocyte Distribution in Bone Marrow, Spleen and Blood.* Neuroimmunomodulation, 2009. **16**(3): p. 191-200.
107. Nash, J.F., Jr., H.Y. Meltzer, and G.A. Gudelsky, *Elevation of serum prolactin and corticosterone concentrations in the rat after the administration of 3,4-methylenedioxymethamphetamine.* J Pharmacol Exp Ther, 1988. **245**(3): p. 873-9.
108. Connor, T.J., J.P. Kelly, and B.E. Leonard, *An assessment of the acute effects of the serotonin releasers methylenedioxymethamphetamine, methylenedioxyamphetamine and fenfluramine on immunity in rats.* Immunopharmacology, 2000. **46**(3): p. 223-35.
109. Fallon, J.K., et al., *Action of MDMA (ecstasy) and its metabolites on arginine vasopressin release.* Ann N Y Acad Sci, 2002. **965**: p. 399-409.
110. Gordon, C.J., *Thermophysiological responses to hyperthermic drugs: extrapolating from rodent to human.* Prog Brain Res, 2007. **162**: p. 63-79.
111. Reveron, M.E., E.Y. Maier, and C.L. Duvauchelle, *Experience-dependent changes in temperature and behavioral activity induced by MDMA.* Physiol Behav, 2006. **89**(3): p. 358-63.
112. Dafters, R.I., *Effect of ambient temperature on hyperthermia and hyperkinesis induced by 3,4-methylenedioxymethamphetamine (MDMA or "ecstasy") in rats.* Psychopharmacology (Berl), 1994. **114**(3): p. 505-8.
113. Fantegrossi, W.E., et al., *Pharmacological characterization of the effects of 3,4-methylenedioxymethamphetamine ("ecstasy") and its enantiomers on lethality, core temperature, and locomotor activity in singly housed and crowded mice.* Psychopharmacology (Berl), 2003. **166**(3): p. 202-11.
114. Malberg, J.E. and L.S. Seiden, *Small changes in ambient temperature cause large changes in 3,4-methylenedioxymethamphetamine (MDMA)-induced serotonin neurotoxicity and core body temperature in the rat.* J Neurosci, 1998. **18**(13): p. 5086-94.
115. Von Huben, S.N., et al., *Impact of ambient temperature on hyperthermia induced by (+/-)3,4-methylenedioxymethamphetamine in rhesus macaques.* Neuropsychopharmacology, 2007. **32**(3): p. 673-81.
116. Bowyer, J.F., et al., *Plasma levels of parent compound and metabolites after doses of either d-fenfluramine or d-3,4-methylenedioxymethamphetamine (MDMA) that produce long-term serotonergic alterations.* Neurotoxicology, 2003. **24**(3): p. 379-90.
117. Freedman, R.R., C.E. Johanson, and M.E. Tancer, *Thermoregulatory effects of 3,4-methylenedioxymethamphetamine (MDMA) in humans.* Psychopharmacology (Berl), 2005. **183**(2): p. 248-56.
118. Crean, R.D., S.A. Davis, and M.A. Taffe, *Oral administration of (+/-)3,4-methylenedioxymethamphetamine and (+)methamphetamine alters temperature and activity in rhesus macaques.* Pharmacol Biochem Behav, 2007. **87**(1): p. 11-9.

119. Crean, R.D., et al., *Effects of (+/-)3,4-methylenedioxymethamphetamine, (+/-)3,4-methylenedioxyamphetamine and methamphetamine on temperature and activity in rhesus macaques.* Neuroscience, 2006. **142**(2): p. 515-25.
120. Banks, M.L., et al., *Ambient temperature effects on 3,4-methylenedioxymethamphetamine-induced thermodysregulation and pharmacokinetics in male monkeys.* Drug Metab Dispos, 2007. **35**(10): p. 1840-5.
121. Bexis, S. and J.R. Docherty, *Effects of MDMA, MDA and MDEA on blood pressure, heart rate, locomotor activity and body temperature in the rat involve alpha-adrenoceptors.* Br J Pharmacol, 2006. **147**(8): p. 926-34.
122. Tiangco, D.A., et al., *3,4-Methylenedioxymethamphetamine activates nuclear factor-kappaB, increases intracellular calcium, and modulates gene transcription in rat heart cells.* Cardiovasc Toxicol, 2005. **5**(3): p. 301-10.
123. Vandeputte, C. and J.R. Docherty, *Vascular actions of 3,4-methylenedioxymethamphetamine in alpha(2A/D)- adrenoceptor knockout mice.* Eur J Pharmacol, 2002. **457**(1): p. 45-9.
124. Bexis, S. and J.R. Docherty, *Role of alpha2A-adrenoceptors in the effects of MDMA on body temperature in the mouse.* Br J Pharmacol, 2005. **146**(1): p. 1-6.
125. Quinn, S.T., et al., *Blockade of noradrenaline transport abolishes 4-methylthioamphetamine-induced contraction of the rat aorta in vitro.* Auton Autacoid Pharmacol, 2006. **26**(4): p. 335-44.
126. Green, A.R., et al., *The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy").* Pharmacol Rev, 2003. **55**(3): p. 463-508.
127. Ho, Y.J., et al., *Acute and long-term consequences of single MDMA administration in relation to individual anxiety levels in the rat.* Behav Brain Res, 2004. **149**(2): p. 135-44.
128. Selken, J. and D.E. Nichols, *Alpha1-adrenergic receptors mediate the locomotor response to systemic administration of (+/-)-3,4-methylenedioxymethamphetamine (MDMA) in rats.* Pharmacol Biochem Behav, 2007. **86**(4): p. 622-30.
129. Thompson, M.R., G.E. Hunt, and I.S. McGregor, *Neural correlates of MDMA ("Ecstasy")-induced social interaction in rats.* Soc Neurosci, 2009. **4**(1): p. 60-72.
130. Hasler, F., et al., *Investigation of serotonin-1A receptor function in the human psychopharmacology of MDMA.* J Psychopharmacol, 2009. **23**(8): p. 923-35.
131. Hysek, C.M., F.X. Vollenweider, and M.E. Liechti, *Effects of a beta-blocker on the cardiovascular response to MDMA (Ecstasy).* Emerg Med J, 2010. **27**(8): p. 586-9.
132. van Wel, J.H., et al., *Blockade of 5-HT(2) Receptor Selectively Prevents MDMA-Induced Verbal Memory Impairment.* Neuropsychopharmacology, 2011. **36**(9): p. 1932-9.
133. Liester, M.B., et al., *Phenomenology and sequelae of 3,4-methylenedioxymethamphetamine use.* J Nerv Ment Dis, 1992. **180**(6): p. 345-52; discussion 353-4.
134. Peroutka, S.J., H. Newman, and H. Harris, *Subjective effects of 3,4-methylenedioxymethamphetamine in recreational users.* Neuropsychopharmacology, 1988. **1**(4): p. 273-7.
135. Callahan, B.T., B.J. Cord, and G.A. Ricaurte, *Long-term impairment of anterograde axonal transport along fiber projections originating in the rostral raphe nuclei after treatment with fenfluramine or methylenedioxymethamphetamine.* Synapse, 2001. **40**(2): p. 113-21.
136. Gurtman, C.G., et al., *Increased anxiety in rats after 3,4-*

methylenedioxymethamphetamine: association with serotonin depletion. Eur J Pharmacol, 2002. **446**(1-3): p. 89-96.

137. Hatzidimitriou, G., U.D. McCann, and G.A. Ricaurte, *Altered serotonin innervation patterns in the forebrain of monkeys treated with (+/-)3,4-methylenedioxymethamphetamine seven years previously: factors influencing abnormal recovery.* J Neurosci, 1999. **19**(12): p. 5096-107.
138. O'Callaghan, J.P. and D.B. Miller, *Neurotoxicity profiles of substituted amphetamines in the C57BL/6J mouse.* J Pharmacol Exp Ther, 1994. **270**(2): p. 741-51.
139. Miller, D.B. and J.P. O'Callaghan, *Neurotoxicity of d-amphetamine in the C57BL/6J and CD-1 mouse. Interactions with stress and the adrenal system.* Ann N Y Acad Sci, 1996. **801**: p. 148-67.
140. Molliver, M.E., et al., *Neurotoxicity of MDMA and related compounds: anatomic studies.* Ann N Y Acad Sci, 1990. **600**: p. 649-61; discussion 661-4.
141. Sabol, K.E., et al., *Amphetamine analogs have differential effects on DRL 36-s schedule performance.* Psychopharmacology (Berl), 1995. **121**(1): p. 57-65.
142. Mayado, A., et al., *Increased interleukin-1beta levels following low dose MDMA induces tolerance against the 5-HT neurotoxicity produced by challenge MDMA.* J Neuroinflammation, 2011. **8**: p. 165.
143. Shen, E.Y., S.F. Ali, and J.S. Meyer, *Chronic administration of THC prevents the behavioral effects of intermittent adolescent MDMA administration and attenuates MDMA-induced hyperthermia and neurotoxicity in rats.* Neuropharmacology, 2011. **61**(8): p. 1183-92.
144. Fantegrossi, W.E., et al., *Nantenine: an antagonist of the behavioral and physiological effects of MDMA in mice.* Psychopharmacology (Berl), 2004. **173**(3-4): p. 270-7.
145. Meyer, J.S., et al., *Neural effects of MDMA as determined by functional magnetic resonance imaging and magnetic resonance spectroscopy in awake marmoset monkeys.* Ann N Y Acad Sci, 2006. **1074**: p. 365-76.
146. Davis, W.M., H.T. Hatoum, and I.W. Waters, *Toxicity of MDA (3,4-methylenedioxyamphetamine) considered for relevance to hazards of MDMA (Ecstasy) abuse.* Alcohol Drug Res, 1987. **7**(3): p. 123-34.
147. Fonsart, J., et al., *Sprague-Dawley rats display metabolism-mediated sex differences in the acute toxicity of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy).* Toxicol Appl Pharmacol, 2008.
148. Malpass, A., et al., *Acute toxicity of 3,4-methylenedioxymethamphetamine (MDMA) in Sprague-Dawley and Dark Agouti rats.* Pharmacol Biochem Behav, 1999. **64**(1): p. 29-34.
149. Palenicek, T., et al., *Increased sensitivity to the acute effects of MDMA ("ecstasy") in female rats.* Physiol Behav, 2005. **86**(4): p. 546-53.
150. Campbell, N.G., et al., *MDMA administration to pregnant Sprague-Dawley rats results in its passage to the fetal compartment.* Neurotoxicol Teratol, 2006. **28**(4): p. 459-65.
151. Koprich, J.B., N.G. Campbell, and J.W. Lipton, *Neonatal 3,4-methylenedioxymethamphetamine (ecstasy) alters dopamine and serotonin neurochemistry and increases brain-derived neurotrophic factor in the forebrain and brainstem of the rat.* Brain Res Dev Brain Res, 2003. **147**(1-2): p. 177-82.
152. Koprich, J.B., et al., *Prenatal 3,4-methylenedioxymethamphetamine (ecstasy) alters exploratory behavior, reduces monoamine metabolism, and increases forebrain tyrosine hydroxylase fiber density of juvenile rats.* Neurotoxicol Teratol, 2003. **25**(5): p. 509-17.

153. Cohen, M.A., et al., *Learning and memory after neonatal exposure to 3,4-methylenedioxymethamphetamine (ecstasy) in rats: interaction with exposure in adulthood.* Synapse, 2005. **57**(3): p. 148-59.
154. Piper, B.J., J.D. Farelli, and J.S. Meyer, *Dissociation between serotonin neurotoxicity and brain-derived neurotrophic factor induction following neonatal MDMA exposure in rats.* Dev Neurosci, 2009. **31**(1-2): p. 90-4.
155. Piper, B.J. and J.S. Meyer, *Increased responsiveness to MDMA in adult rats treated neonatally with MDMA.* Neurotoxicol Teratol, 2006. **28**(1): p. 95-102.
156. Green, A.R., et al., *Studies on the effect of MDMA ('ecstasy') on the body temperature of rats housed at different ambient room temperatures.* Br J Pharmacol, 2005. **146**(2): p. 306-12.
157. Skelton, M.R., et al., *Distinct periods of developmental sensitivity to the effects of 3,4-(+/-)-methylenedioxymethamphetamine (MDMA) on behaviour and monoamines in rats.* Int J Neuropsychopharmacol, 2012. **15**(6): p. 811-24.
158. Fantegrossi, W.E., et al., *Behavioral and neurochemical consequences of long-term intravenous self-administration of MDMA and its enantiomers by rhesus monkeys.* Neuropsychopharmacology, 2004. **29**(7): p. 1270-81.
159. Schenk, S., et al., *Development, maintenance and temporal pattern of self-administration maintained by ecstasy (MDMA) in rats.* Psychopharmacology (Berl), 2003. **169**(1): p. 21-7.
160. Trigo, J.M., et al., *A reliable model of intravenous MDMA self-administration in naive mice.* Psychopharmacology (Berl), 2006. **184**(2): p. 212-20.
161. Lile, J.A., J.T. Ross, and M.A. Nader, *A comparison of the reinforcing efficacy of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy") with cocaine in rhesus monkeys.* Drug Alcohol Depend, 2005. **78**(2): p. 135-40.
162. Wang, Z. and W.L. Woolverton, *Estimating the relative reinforcing strength of (+/-)-3,4-methylenedioxymethamphetamine (MDMA) and its isomers in rhesus monkeys: comparison to (+)-methamphetamine.* Psychopharmacology (Berl), 2007. **189**(4): p. 483-8.
163. Gaston, T.R., Rasmussen, G. T., *Identification of 3,4-methylenedioxy-n-methylamphetamine;.* Microgram, 1972. **5**: p. 60-63.
164. Stolaroff, M., *The Secret Chief Revealed: Conversations with a pioneer of the underground therapy movement.* 2004, Sarasota FL: Multidisciplinary Association for Psychedelic Studies.
165. Greer, G. and R. Tolbert, *Subjective reports of the effects of MDMA in a clinical setting.* J Psychoactive Drugs, 1986. **18**(4): p. 319-27.
166. Mithoefer, M.C., et al., *Durability of improvement in post-traumatic stress disorder symptoms and absence of harmful effects or drug dependency after 3,4-methylenedioxymethamphetamine-assisted psychotherapy: a prospective long-term follow-up study.* J Psychopharmacol, 2013. **27**(1): p. 28-39.
167. Oehen, P., et al., *A randomized, controlled pilot study of MDMA (+/- 3,4-Methylenedioxymethamphetamine)-assisted psychotherapy for treatment of resistant, chronic Post-Traumatic Stress Disorder (PTSD).* J Psychopharmacol, 2013. **27**(1): p. 40-52.
168. Gouzoulis-Mayfrank, E., et al., *Psychopathological, neuroendocrine and autonomic effects of 3,4-methylenedioxyethylamphetamine (MDE), psilocybin and d-methamphetamine in healthy volunteers. Results of an experimental double-blind*

placebo-controlled study. Psychopharmacology (Berl), 1999. **142**(1): p. 41-50.
169. Davison, D. and A.C. Parrott, *Ecstasy (MDMA) in recreational users: Self-reported psychological and physiological effects.* Human Psychopharmacology Clinical & Experimental, 1997. **12**(3): p. 221-226.
170. Liechti, M.E., et al., *Acute psychological effects of 3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy") are attenuated by the serotonin uptake inhibitor citalopram.* Neuropsychopharmacology, 2000. **22**(5): p. 513-21.
171. Liechti, M.E. and F.X. Vollenweider, *The serotonin uptake inhibitor citalopram reduces acute cardiovascular and vegetative effects of 3,4-methylenedioxymethamphetamine ('Ecstasy') in healthy volunteers.* J Psychopharmacol, 2000. **14**(3): p. 269-74.
172. Pacifici, R., et al., *Paroxetine inhibits acute effects of 3,4-methylenedioxymethamphetamine on the immune system in humans.* J Pharmacol Exp Ther, 2004. **309**(1): p. 285-92.
173. Tancer, M. and C.E. Johanson, *The effects of fluoxetine on the subjective and physiological effects of 3,4-methylenedioxymethamphetamine (MDMA) in humans.* Psychopharmacology (Berl), 2007. **189**(4): p. 565-73.
174. Farre, M., et al., *Pharmacological Interaction Between 3,4-Methylenedioxymethamphetamine (MDMA, ecstasy) and Paroxetine: Pharmacological effects and pharmacokinetics.* J Pharmacol Exp Ther, 2007.
175. Liechti, M.E., et al., *Psychological and physiological effects of MDMA ("Ecstasy") after pretreatment with the 5-HT(2) antagonist ketanserin in healthy humans.* Neuropsychopharmacology, 2000. **23**(4): p. 396-404.
176. Hysek, C.M., et al., *Effects of the alpha(2)-adrenergic agonist clonidine on the pharmacodynamics and pharmacokinetics of 3,4-methylenedioxymethamphetamine in healthy volunteers.* J Pharmacol Exp Ther, 2012. **340**(2): p. 286-94.
177. Hysek, C.M., et al., *The norepinephrine transporter inhibitor reboxetine reduces stimulant effects of MDMA ("ecstasy") in humans.* Clin Pharmacol Ther, 2011. **90**(2): p. 246-55.
178. Hysek, C.M., et al., *Duloxetine inhibits effects of MDMA ("ecstasy") in vitro and in humans in a randomized placebo-controlled laboratory study.* PLoS One, 2012. **7**(5): p. e36476.
179. Simmler, L.D., C.M. Hysek, and M.E. Liechti, *Sex differences in the effects of MDMA (ecstasy) on plasma copeptin in healthy subjects.* J Clin Endocrinol Metab, 2011. **96**(9): p. 2844-50.
180. Liechti, M.E. and F.X. Vollenweider, *Acute psychological and physiological effects of MDMA ("Ecstasy") after haloperidol pretreatment in healthy humans.* Eur Neuropsychopharmacol, 2000. **10**(4): p. 289-95.
181. de la Torre, R. and M. Farre, *Neurotoxicity of MDMA (ecstasy): the limitations of scaling from animals to humans.* Trends Pharmacol Sci, 2004. **25**(10): p. 505-8.
182. de Boer, D., et al., *Gas chromatographic/mass spectrometric assay for profiling the enantiomers of 3,4-methylenedioxymethamphetamine and its chiral metabolites using positive chemical ionization ion trap mass spectrometry.* J Mass Spectrom, 1997. **32**(11): p. 1236-46.
183. Helmlin, H.J., et al., *Analysis of 3,4-methylenedioxymethamphetamine (MDMA) and its metabolites in plasma and urine by HPLC-DAD and GC-MS.* J Anal Toxicol, 1996. **20**(6): p. 432-40.
184. Lanz, M., R. Brenneisen, and W. Thormann, *Enantioselective determination of 3,4-*

methylene-dioxymethamphetamine and two of its metabolites in human urine by cyclodextrin-modified capillary zone electrophoresis. Electrophoresis, 1997. **18**(6): p. 1035-43.

185. Ortuno, J., et al., *Quantification of 3,4-methylenedioxymetamphetamine and its metabolites in plasma and urine by gas chromatography with nitrogen-phosphorus detection.* J Chromatogr B Biomed Sci Appl, 1999. **723**(1-2): p. 221-32.
186. Helmlin, H.J. and R. Brenneisen, *Determination of psychotropic phenylalkylamine derivatives in biological matrices by high-performance liquid chromatography with photodiode-array detection.* J Chromatogr, 1992. **593**(1-2): p. 87-94.
187. Farre, M., et al., *Repeated doses administration of MDMA in humans: pharmacological effects and pharmacokinetics.* Psychopharmacology (Berl), 2004. **173**(3-4): p. 364-75.
188. Pizarro, N., et al., *Stereochemical analysis of 3,4-methylenedioxymethamphetamine and its main metabolites in human samples including the catechol-type metabolite (3,4-dihydroxymethamphetamine).* Drug Metab Dispos, 2004. **32**(9): p. 1001-7.
189. Pizarro, N., et al., *Stereochemical analysis of 3,4-methylenedioxymethamphetamine and its main metabolites by gas chromatography/mass spectrometry.* Rapid Commun Mass Spectrom, 2003. **17**(4): p. 330-6.
190. Pizarro, N., et al., *Determination of MDMA and its metabolites in blood and urine by gas chromatography-mass spectrometry and analysis of enantiomers by capillary electrophoresis.* J Anal Toxicol, 2002. **26**(3): p. 157-65.
191. Segura, M., et al., *3,4-Dihydroxymethamphetamine (HHMA). A Major in Vivo 3,4-methylenedioxymethamphetamine (MDMA) Metabolite in Humans.* Chem Res Toxicol, 2001. **14**(9): p. 1203-1208.
192. de la Torre, R., et al., *Human pharmacology of MDMA: pharmacokinetics, metabolism, and disposition.* Ther Drug Monit, 2004. **26**(2): p. 137-44.
193. Abraham, T.T., et al., *Urinary MDMA, MDA, HMMA, and HMA excretion following controlled MDMA administration to humans.* J Anal Toxicol, 2009. **33**(8): p. 439-46.
194. Peiro, A.M., et al., *Human pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) after repeated doses taken 2 h apart.* Psychopharmacology (Berl), 2013. **225**(4): p. 883-93.
195. Fallon, J.K., et al., *Stereospecific analysis and enantiomeric disposition of 3, 4-methylenedioxymethamphetamine (Ecstasy) in humans [published erratum appears in Clin Chem 1999 Sep;45(9):1585].* Clin Chem, 1999. **45**(7): p. 1058-69.
196. Schwaninger, A.E., et al., *Stereoselective urinary MDMA (ecstasy) and metabolites excretion kinetics following controlled MDMA administration to humans.* Biochem Pharmacol, 2012. **83**(1): p. 131-8.
197. O'Mathuna, B., et al., *The consequences of 3,4-methylenedioxymethamphetamine induced CYP2D6 inhibition in humans.* J Clin Psychopharmacol, 2008. **28**(5): p. 523-9.
198. Yubero-Lahoz, S., et al., *Sex Differences in 3,4-Methylenedioxymethamphetamine (MDMA; Ecstasy)-Induced Cytochrome P450 2D6 Inhibition in Humans.* Clin Pharmacokinet, 2011. **50**(5): p. 319-29.
199. de la Torre, R., et al., *MDMA, methamphetamine, and CYP2D6 pharmacogenetics: what is clinically relevant?* Front Genet, 2012. **3**: p. 235.
200. Yubero-Lahoz, S., et al., *Changes in CYP1A2 activity in humans after 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) administration using caffeine as a probe drug.* Drug Metab Pharmacokinet, 2012. **27**(6): p. 605-13.
201. Pardo-Lozano, R., et al., *Clinical Pharmacology of 3,4-Methylenedioxymethamphetamine*

(MDMA, "Ecstasy"): The Influence of Gender and Genetics (CYP2D6, COMT, 5-HTT). PLoS One, 2012. **7**(10): p. e47599.

202. Grob, C., *Unpublished data on human study of psychological and physiological effects of MDMA*. 2001.
203. Pacifici, R., et al., *Cell-mediated immune response in MDMA users after repeated dose administration: studies in controlled versus noncontrolled settings.* Ann N Y Acad Sci, 2002. **965**: p. 421-33.
204. Parrott, A.C., et al., *Dance clubbing on MDMA and during abstinence from Ecstasy/MDMA: prospective neuroendocrine and psychobiological changes.* Neuropsychobiology, 2008. **57**(4): p. 165-80.
205. Wolff, K., et al., *Vasopressin and oxytocin secretion in response to the consumption of ecstasy in a clubbing population.* J Psychopharmacol, 2006. **20**(3): p. 400-10.
206. Domes, G., et al., *Oxytocin Attenuates Amygdala Responses to Emotional Faces Regardless of Valence.* Biol Psychiatry, 2007.
207. Kirsch, P., et al., *Oxytocin modulates neural circuitry for social cognition and fear in humans.* J Neurosci, 2005. **25**(49): p. 11489-93.
208. Bartz, J.A. and E. Hollander, *The neuroscience of affiliation: forging links between basic and clinical research on neuropeptides and social behavior.* Horm Behav, 2006. **50**(4): p. 518-28.
209. Wirth, M.M. and O.C. Schultheiss, *Effects of affiliation arousal (hope of closeness) and affiliation stress (fear of rejection) on progesterone and cortisol.* Horm Behav, 2006. **50**(5): p. 786-95.
210. Kuypers, K.P., et al., *Inhibition of MDMA-induced increase in cortisol does not prevent acute impairment of verbal memory.* Br J Pharmacol, 2013. **168**(3): p. 607-17.
211. Brvar, M., et al., *Polydipsia as another mechanism of hyponatremia after 'ecstasy' (3,4 methyldioxymethamphetamine) ingestion.* Eur J Emerg Med, 2004. **11**(5): p. 302-4.
212. Henry, J.A. and J.G. Rella, *Medical risks associated with MDMA use*, in *Ecstasy: A Complete Guide*, J. Holland, Editor. 2001, Inner Traditions: Rochester, VT. p. 71-86.
213. Rosenson, J., et al., *Patterns of ecstasy-associated hyponatremia in California.* Ann Emerg Med, 2007. **49**(2): p. 164-71, 171 e1.
214. Irvine, R.J., et al., *Plasma drug concentrations and physiological measures in 'dance party' participants.* Neuropsychopharmacology, 2006. **31**(2): p. 424-30.
215. Cole, J.C., et al., *Preliminary evidence of the cardiovascular effects of polysubstance misuse in nightclubs.* J Psychopharmacol, 2005. **19**(1): p. 67-70.
216. Liechti, M.E., I. Kunz, and H. Kupferschmidt, *Acute medical problems due to Ecstasy use. Case-series of emergency department visits.* Swiss Med Wkly, 2005. **135**(43-44): p. 652-7.
217. Greene, S.L., et al., *Multiple toxicity from 3,4-methylenedioxymethamphetamine ("ecstasy").* Am J Emerg Med, 2003. **21**(2): p. 121-4.
218. Martin, T.L., D.A. Chiasson, and S.J. Kish, *Does hyperthyroidism increase risk of death due to the ingestion of ecstasy?* J Forensic Sci, 2007. **52**(4): p. 951-3.
219. Sprague, J.E., et al., *Roles of norepinephrine, free Fatty acids, thyroid status, and skeletal muscle uncoupling protein 3 expression in sympathomimetic-induced thermogenesis.* J Pharmacol Exp Ther, 2007. **320**(1): p. 274-80.
220. Hysek, C., et al., *Carvedilol inhibits the cardiostimulant and thermogenic effects of MDMA in humans.* Br J Pharmacol, 2012. **166**(8): p. 2277-88.
221. Baggott, M.J., et al., *3,4-Methylenedioxymethamphetamine (MDMA, 'Ecstasy') and*

Prazosin Interactions in Humans., in *70th Annual Meeting of the College on Problems of Drug Dependence*. 2008: San Juan, Puerto Rico.
222. Hughes, J.C., M. McCabe, and R.J. Evans, *Intracranial haemorrhage associated with ingestion of 'ecstasy'.* Arch Emerg Med, 1993. **10**(4): p. 372-4.
223. Kaku, D.A. and D.H. Lowenstein, *Emergence of recreational drug abuse as a major risk factor for stroke in young adults.* Ann Intern Med, 1990. **113**(11): p. 821-7.
224. Perez, J.A., Jr., E.L. Arsura, and S. Strategos, *Methamphetamine-related stroke: four cases.* J Emerg Med, 1999. **17**(3): p. 469-71.
225. Rothwell, P.M. and R. Grant, *Cerebral venous sinus thrombosis induced by 'ecstasy'.* J Neurol Neurosurg Psychiatry, 1993. **56**(9): p. 1035.
226. Gledhill, J.A., et al., *Subarachnoid haemorrhage associated with MDMA abuse [letter].* J Neurol Neurosurg Psychiatry, 1993. **56**(9): p. 1036-7.
227. Manchanda, S. and M.J. Connolly, *Cerebral infarction in association with Ecstasy abuse.* Postgrad Med J, 1993. **69**(817): p. 874-5.
228. Selmi, F., et al., *Intracerebral haemorrhage due to amphetamine abuse: report of two cases with underlying arteriovenous malformations.* Br J Neurosurg, 1995. **9**(1): p. 93-6.
229. Ho, M.P., J.L. Tsai, and Y.K. Wong, *Subarachnoid hemorrhage and death following coingestion of MDMA with other drugs.* J Chin Med Assoc, 2004. **67**(12): p. 640-3.
230. Dowling, G.P., E.T.d. McDonough, and R.O. Bost, *'Eve' and 'Ecstasy'. A report of five deaths associated with the use of MDEA and MDMA.* Jama, 1987. **257**(12): p. 1615-7.
231. Milroy, C.M., J.C. Clark, and A.R. Forrest, *Pathology of deaths associated with "ecstasy" and "eve" misuse.* J Clin Pathol, 1996. **49**(2): p. 149-53.
232. Droogmans, S., et al., *Possible association between 3,4-methylenedioxymethamphetamine abuse and valvular heart disease.* Am J Cardiol, 2007. **100**(9): p. 1442-5.
233. Montastruc, F., et al., *Valvular heart disease in a patient taking 3,4-methylenedioxymethamphetamine (MDMA, 'Ecstasy').* Br J Clin Pharmacol, 2012. **74**(3): p. 547-8.
234. Carvalho, M., et al., *Mechanisms underlying the hepatotoxic effects of ecstasy.* Curr Pharm Biotechnol, 2010. **11**(5): p. 476-95.
235. Dykhuizen, R.S., et al., *Ecstasy induced hepatitis mimicking viral hepatitis.* Gut, 1995. **36**(6): p. 939-41.
236. Ellis, A.J., et al., *Acute liver damage and ecstasy ingestion.* Gut, 1996. **38**(3): p. 454-8.
237. Ellis, S.J., *Complications of "ecstasy" misuse.* Lancet, 1992. **340**(8821): p. 726.
238. Andreu, V., et al., *Ecstasy: a common cause of severe acute hepatotoxicity.* J Hepatol, 1998. **29**(3): p. 394-7.
239. Frith, C.H., et al., *Toxicity of methylenedioxymethamphetamine (MDMA) in the dog and the rat.* Fundam Appl Toxicol, 1987. **9**(1): p. 110-9.
240. Beitia, G., et al., *Ecstasy-induced toxicity in rat liver.* Liver, 2000. **20**(1): p. 8-15.
241. Varela-Rey, M., et al., *3,4-methylenedioxymethamphetamine ("Ecstasy") stimulates the expression of alpha1(I) procollagen mRNA in hepatic stellate cells.* Biochem Biophys Res Commun, 1999. **259**(3): p. 678-82.
242. Carvalho, M., F. Carvalho, and M.L. Bastos, *Is hyperthermia the triggering factor for hepatotoxicity induced by 3,4- methylenedioxymethamphetamine (ecstasy)? An in vitro study using freshly isolated mouse hepatocytes.* Arch Toxicol, 2001. **74**(12): p. 789-93.
243. Pacifici, R., et al., *Immunomodulating activity of MDMA.* Ann N Y Acad Sci, 2000. **914**: p. 215-24.